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B cell activation is an energetically demanding process during which B lymphocytes 
undergo reprogramming and shift from a resting state to a highly proliferative, 
metabolically active state. Little is known about the metabolic reprogramming process or 
the role extracellular nutrients play in the activation response.  Here we demonstrate that 
there are distinct requirements for the nutrients L-glutamine and glucose during 
activation.  We show that cells activated in glucose-depleted conditions are still able to 
undergo growth and signaling events.  In contrast, we show that extracellular L-
glutamine is essential for all but the earliest activation events, and cells cultured in L-
glutamine-deprived conditions are unable to enter the cell cycle. Consistently, we show 
that extracellular supplementation of the cell-permeable derivative of α-ketoglutarate (α-
KG), a glutaminolytic product, is able to rescue cell activation in the absence of 
glutamine.  We also show the induction of the high affinity amino acid transporter 
ASCT2 is required for glutamine uptake following B cell receptor (BCR) crosslinking. 
Specifically, we found that halting glutamine uptake or processing by inhibiting ASCT2 
or the glutaminolytic enzyme glutaminase causes activation defects that parallel those 
observed in glutamine deprived conditions, indicating a requirement for glutaminolysis 
during the very early stages of activation.  We found that a-KG does not contribute to 
epigenetic remodeling, but is necessary for mammalian target of rapamycin complex 1 
	(mTORC1) activation.  In turn, mTORC1 activity is required for upregulation of the 
glucose transporter Glut1 during the initial 24 hours of activation, as well as increased 
glucose uptake.  These findings indicate a distinct metabolic profile that begins with 
glutamine uptake, and acts through mTORC1 signaling to later promote glucose uptake.  
Finally, we show that nutrients contribute to functional differentiation events during B 
cell activation.  Glucose is required to support biogenesis of the endoplasmic reticulum 
as well as differentiation into plasma-like cells, while glutamine is required to support 
differentiation into IL-10 secreting regulatory B cell subsets.  The requirement for 
glutamine for in vitro B10 cell differentiation is the first reported link between nutrient 
signaling and regulatory B cell development, and is a novel finding in the field. 
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CHAPTER ONE 
Introduction 
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The immune system is a tightly regulated system that serves to provide 
protection to an organism from outside pathogens while at the same time maintaining 
tolerance to self.  To provide these functions, the immune system must be capable of 
quickly sensing and identifying foreign cells/tissues and substances, and acting in a 
coordinated manner to eliminate these invading pathogens.  In mammals, the immune 
system consists of two branches, the innate and adaptive components, which cooperate 
to identify and eliminate pathogens.  Innate immunity functions as the initial, 
nonspecific, arm of the immune system that is capable of quickly recognizing a diverse 
array of pathogens and then rapidly triggering an effector response.  The adaptive branch 
of immunity provides a response that is highly specific, providing sterilizing immunity, 
and contributes to the development of immune memory. 
The adaptive immune response is influenced by the innate immune system, and is 
essential when the early response provided by innate immunity fails to eliminate foreign 
pathogens.  The adaptive immune response is mediated by lymphocytes, including CD8+ 
cytotoxic T lymphocytes (CD8+ T cells), CD4+ T helper lymphocytes (CD4+ Th cells), 
and B lymphocytes (B cells).1  Cross-talk and intercellular communication between 
these cells, as well as other immune cell types, is essential for proper function of the 
adaptive immune response.  B cells are tightly regulated throughout development and 
during maturity by signals from their environment, including antigen recognition at cell 
surface receptors, as well as by cytokine signals and ligation of co-stimulatory molecules 
by CD4+ Th cells.  These signals regulate the survival, clonal expansion, and 
differentiation of mature B cells. 
The mouse immune system in many ways closely resembles that of humans, 
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which provides a convenient platform from which to study cell types and processes that 
would otherwise be difficult or impossible to analyze.  For this reason mouse models 
have been used for decades as an important tool in conjunction with the study of human 
immunology.  Throughout this introduction, processes involved in immune cell 
development, signaling, and biochemical events shall be discussed that pertain to the 
immune systems of either mouse, human, or both. 
 
B Lymphocyte Development 
 The development of white blood cells is a highly regulated process wherein 
hematopoietic stem cell (HSC) progenitors give rise to a diverse set of immune cell 
subsets.2  During embryonic development, this process takes place in the fetal liver, and 
gives rise to the so called B1 subset of B cells that are enriched in the mucosal surfaces 
and peritoneal cavity.3-6  Throughout the course of adult life, HSC differentiation occurs 
in the bone marrow to produce additional B1 cells and the B2 subset of B cells.7  The B2 
subset is enriched in the secondary lymphoid organs including spleen and lymph nodes, 
and will be the primary B cell population used in my investigations.8,9  
 In the bone marrow, specific gene expression programs, cytokines, and cues from 
the environment and surrounding cells direct the differentiation of HSC progenitors into 
three major blood lineages: the erythroid, myeloid, and lymphoid lineages.10-12  
Development of B cells from HSCs occurs in distinct stages according to these signals, 
and is extensively regulated by expression of specific genes, the ability to produce 
functional antigen receptor, and the elimination of self-reactive B cells.13-15 To illustrate, 
prior to B cell lineage commitment, B cells exist in the bone marrow as a common 
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lymphoid progenitor (CLP) subset that can give rise to B, T, and NK cells.16  
Differentiation of CD34+ HSCs to CLPs is driven by the expression of E2A, pu.1, and 
ikaros genes, and characterized by expression of IL-7R-alpha and c-kit.17,18  Stromal 
cells in the bone marrow initiate the process of B cell commitment from CLPs by 
secreting IL-7, in part, to induce expression of terminal deoxynucleotidyl transferase 
(TdT) and V(D)J recombinase enzymes RAG1 and RAG2 that begin antigen-receptor 
gene rearrangement.17,19,20 The earliest committed B cells, progenitor B cells (pro-B), 
can be distinguished in the mouse by the surface expression of the CD45R isoform B220 
and Class II MHC molecule along with the Pax5 and FOXO1 transcription factors.21   
Finally, the cells undergo joining of the D-J segments on the immunoglobulin heavy (H) 
chain locus.22 
 Pro-B cells transition to pre-B cells following the V segment joining on the H 
chain of the immunoglobulin heavy (H) chain locus (Figure 1).  The pre-B cell also 
begins to express surrogate light chain (SLC) to produce a functional pre-BCR at the cell 
surface, which is critical to the cell’s survival.23 Successfully rearranged H chain 
together with Igα and Igβ heterodimer molecules expressed on the cell surface form a 
pre-BCR complex that functions to confirm activity and screen for self-reactivity and 
commit the pre-B cell to inactivate RAG enzymes and halt further H chain 
rearrangement.24-26  After several rounds of proliferation, cells initiate re-expression of 
the RAG enzymes for light (L) chain rearrangement and V-J joining.27  B cells will then 
express surface IgM and become an immature B cell.  This stage is highly susceptible to 
antigen binding, and if self-antigen is recognized in the bone marrow the immature B 
cell will undergo one of three fates:  BCR induced cell death (negative selection), 
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inactivation/ anergy, or receptor editing to generate a non auto-reactive BCR.28  If no 
self-antigen is bound, the immature B cell will exit the bone marrow as a transitional B 
cell.   
        
Figure 1.  B cell development, adapted and reprinted with permission from (29).  B cell 
development is directed by a variety of growth factors and cytokines in the 
microenvironment, and regulated by the expression of functional BCR components.29 
 
 Final stages of B cell development to the mature stage take place in the spleen. 
Although transitional B cells express surface IgM, they are unable to productively 
respond to antigen.  Instead, antigen encounter can lead to anergy and apoptosis, 
allowing deletion of cells that respond to self-antigen in the periphery that may not have 
been present in the bone marrow.30  If no autoreactivity occurs, the transitional B cell 
undergoes a differentiation into either a mature Marginal Zone (MZ) or Follicular (FO) 
B cell.8,31  The mature, resting B cell then resides in the spleen and awaits encounter 
with cognate antigen.   
 In the spleen and lymph nodes, mature B cells that encounter antigen can follow 
two distinct differentiation paths.  Some B cells are capable of undergoing rapid, T cell-
independent differentiation to become low-affinity plasmablasts.  These cells mostly 
secrete IgM, and provide an earlier, but less specific antibody response. Activated B cell 
differentiation can also depend on interaction and costimulation by follicular dendritic 
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cells (FDCs) and CD4+ Th cells.32  This signaling provided by CD4+ Th cells is 
essential for the process of class switching and affinity maturation of the BCR, and 
contributes to B cell survival, clonal expansion, and terminal differentiation.33  BCR 
crosslinking alone is not enough to commit the cell to differentiation without additional 
signals from CD4+ Th cells.  The interaction between B cells, CD4+ Th cells, and FDCs 
constitutes the germinal center (GC) reaction.  B cells that have undergone affinity 
maturation and selection in the GC are able to provide an antibody response with 
maximum binding affinity for antigen.  It is these high affinity B cells that are able to 
undergo terminal differentiation to long-lived antibody secreting plasma cells and 
circulating high affinity memory B cells.34,35 
 Within the mouse, 5 x 107 B cells are produced daily in the bone marrow, while 
only 2-5% survive to become mature circulating B cells.36 This strict selection process is 
essential, as failure to remove or edit self-reactive B cells at any point can lead to a host 
of autoimmune disease states, including systemic lupus encephalitis (SLE) and 
rheumatoid arthritis (RA).37,38  In an adult mouse, there are approximately 109 
circulating mature B cells, with lifespans ranging from several days in the case of naïve 
cells up to a lifetime for terminally differentiated memory cells.39-41  
 
B cell activation and the role of B cell receptor signaling 
 Naïve mature B cells respond to environmental cues and signals and initiate G1 
entry during a process known as activation.  This response is rapidly initiated following 
the interaction of antigen with surface receptors on a mature B cell.  Following 
activation, B cells undergo metabolic reprogramming, allowing them to grow and 
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transition from the G0 phase of the cell cycle to G1, characterized by an increase in 
biomass.42,43 Upregulation of metabolism and growth are also required for new DNA 
synthesis, which allows proliferation and clonal expansion.44 The hallmarks of the 
metabolic shift following activation in B cells have been observed in a wide variety of 
proliferating cells, including activated T lymphocytes, cancer cells, and hepatocytes.45  
 B cells are capable of recognition of specific antigen through a receptor-signaling 
complex located at the plasma membrane, the B cell receptor (BCR).  The BCR is a 
membrane bound form of immunoglobulin (Ig) composed of two identical heavy chains 
and two identical light chains, covalently bound to form the complete receptor.46  This 
extracellular portion of the receptor recognizes antigen at highly variable unique regions, 
providing specificity to the B cell clone.  The BCR is also noncovalently associated with 
an Igα and Igβ heterodimer, which provides the intracellular signal transduction 
response following antigen binding.47-50 Antigen recognition induces clustering of 
individual BCRs and signaling molecules into lipid raft microdomains, which act as a 
nucleation site for the initiation of signaling events.51-53  Clustering of the receptors is 
enhanced through recognition of multivalent antigen by multiple BCR domains, and is 
essential for the propagation of signal intracellularly.54  Following clustering into these 
microdomains a signaling cascade begins, initiated by tyrosine-based activation motifs 
(ITAMS) contained within the Igα/Igβ dimer.50,55 ITAMs act as targets for Src family 
protein tyrosine kinases (PTKs) such as Lyn, and once phosphorylated can be bound by 
the SH2 domain of Syk kinase (Figure 2).56-59  Syk kinase can then recruit proteins such 
as B cell linker protein (BLNK), which activates major signaling pathways including  
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Figure 2. B cell activation by antigen 
recognition at the BCR, adapted and reprinted 
with permission from (75). Initiation of the 
activation response in B cells begins with 
antigen binding at the BCR.  This signal is 
propagated into the cytoplasm by the 
activation of the ITAMs on the associated 
Igα/Igβ heterodimer.  Tyrosine kinases 
(SYK, BTK) and adaptor proteins (BLNK) 
are recruited to amplify the signal, which 
activates major signaling pathways such as 
PI3K/AKT signaling pathway, culminating in 
the activation of transcription factors (NFAT, 
MYC, JUN) that regulate cellular growth and 
proliferation.60  
 
 
 
Ras/MAPK, PLCγ2, and PI3K/Akt, eventually leading to metabolic re-programming, 
cytoskeletal re-organization, and the expression of transcription factors such as c-myc, c-
jun, and NFκB (Figure 2).61-67 
 When the BCR is engaged, it triggers B cells through these signaling pathways to 
express a series of proteins that are necessary for a productive immune response. 
Because expression of these proteins is indicative of B cell activation and have 
established induction timelines, they are commonly used as activation markers. Some of 
the most frequently utilized early activation markers are CD86 and CD71.68 CD86, also 
known as B7-2, acts as a costimulatory molecule for CD4+ Th cell activation by binding 
CD28 on the Th cell surface during formation of the immunological synapse.69  The 
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protein is expressed at very low levels on resting B cells but is upregulated as early as 6 
hours following BCR ligation, with maximum expression reached between 18 and 24 
hours after activation.70 CD71 is the transferrin receptor, necessary for importing iron in 
complex with transferrin by receptor-mediated endocytosis.71  It is expressed at high 
levels on all proliferating cells due to iron requirements, and is maximally induced in B 
cells 24-48 hours after activation.72,73   
 Naïve B cells can be activated in vitro in several different manners, with different 
mechanisms of activation acting through different signaling mechanisms and eliciting 
different effector responses.  The two main types of activation of B cells in vivo are T-
dependent (TD), which includes limited crosslinking of the BCR by proteins and 
requires costimulation and cytokine signaling from CD4+ Th cells, and T-independent 
(TI), mediated by repetitive molecules that have either a strong propensity to crosslink 
the BCR (TI-2 type) or are recognized by germ line encoded receptors such as Toll-like 
receptors (TLR) (TI-1 type).74-76  TI activation, especially of the TI-2 type, can also be 
further augmented by CD4+ Th cell costimulation.77,78  These three traditional activation 
mechanisms can be replicated in vitro.  In vitro, TD activation of B cells can be 
mimicked by adding anti-CD40 and IL4, to recapitulate the cytokine secretion and co-
ligation that would normally occur during the interaction of CD4+ Th cells and B 
cells.78-80  To replicate TI-1 activation, LPS is the typical stimulant used in murine B 
cells, although it is not active in human B cells.  LPS causes polyclonal activation 
through recognition by the TLR4 complex.81,82  These two methods of in vitro 
stimulation cause extensive proliferation, as well as differentiation, marked by 
endomembrane expansion and upregulation of plasma cells markers, culminating in Ig 
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secretion.83-85  TI-2 activation can be imitated by addition of an anti-IgM Ab.  This will 
result in a modest proliferation response with a high percentage of cells undergoing 
apoptosis, but with the benefit of synchronous cell cycle entry for ease of analysis.86-88  
Apoptosis can be ameliorated by the addition of cytokines such as IL-4 or BAFF.77,89  It 
is also essential to only expose naïve B cells to the F(ab’)2 fragment of antibodies for 
stimulation, as Fc receptors on the B cell surface will recognize whole Ab and initiate a 
negative regulatory response.90,91   
 
 
B cell effector functions  
 One of the most well described functions of B cells in the immune system is the 
production and secretion of antibody, however B cells in the periphery have diverse 
effector functions.  Both high and low affinity secreted antibody is an essential 
component of immunity, and actually can trigger a varied set of effector functions.92 
Antibodies are capable of directly binding antigen and coating the surface of an invading 
cell, in a process known as opsonization.  This prevents the pathogen from invading and 
injuring other cells.93,94  Direct binding of pathogens also alerts other immune effector 
cells that are capable of recognizing the Fc’ fragment of antibody to the presence of the 
invader, allowing them to recognize pathogen and mount a response, in a process known 
as antibody-dependent cell-mediated cytotoxicity (ADCC).95-97  Finally, antibodies can 
bind and fix (activate) complement to eliminate invading pathogens.98,99  
 In addition to the functions of antibody itself, B cells perform cellular immune 
tasks as well.  One of the other key functions of B cells in the periphery is to act as 
antigen presenting cells (APCs) to activate CD4+ Th cells.100,101  Unlike CD4+ Th cells, 
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B cells are capable of recognizing whole antigen in a native state at the BCR.  Following 
antigen recognition of a protein-based antigen, B cells quickly begin endocytosis of 
BCR-antigen in complex, and shuttle antigen to the lysosome where it can undergo 
antigen processing and loading onto MHC-II to be redirected to the cell surface.102  
MHC-II presents short peptide fragments that can be recognized by the TCR, prompting 
the CD4+ Th cell to co-ligate B cells at CD40 to form the immunological synapse, a 
close interface through which B and CD4+ Th cells can send signals such as through 
cytokine release (IL-4, -2, -5) and uptake.103,104  B cells are quite proficient at antigen 
processing and presentation, and act as professional APCs. 
 Similarly to CD4+ Th cells, B cells that have been activated can undergo 
differentiation into distinct types of effector cells to mediate specific responses.  Plasma 
cells and memory cells are two of these effector types, and have been mentioned above.  
Additionally, newly activated B cells differentiate into three known classes of effectors 
that are characterized by their cytokine secretion profile.105,106  The first of these 
subtypes is the IL-10 and TGFβ secreting B regulatory cell (Breg).106,107  B cells 
differentiate into the Breg subtype at low percentages following stimulation of BCR, 
CD40, or TLRs.108-110  These cells are capable of CD4+ Th cell suppression, and have 
been shown to prevent induction of autoimmune disease in several mouse models.111-116  
Two B cell subtypes that positively modulate CD4+ Th cell activity have been identified 
with distinct cytokine secretion profiles.117  B effector 1 (Be1) cells are generated in 
response to antigen and Th1 cell signals, and secrete cytokines indicative of a type 1 
immune response including interferon-γ (IFN-γ) and IL-12.117-120  These cells can be 
induced without direct interaction with Th1 cells but in the presence of Th1 type 
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cytokines and TLR agonists.121,122  B effector 2 (Be2) cells are generated in response to 
antigen and Th2 stimulation, and secrete cytokines characteristic of allergy responses, 
including IL-4, IL-6, and IL-2.123  Differentiation into the Be2 subtype requires IL-4 
stimulation and CD40 and CD80/86 coengagement, and unlike Be1 cells is strictly 
dependent on T cell interactions (Th2 cells).124 
 Although the study of B effector cells is a relatively new and under-represented 
field, encouraging results have already been observed in the use of effector B cell 
depletion as a therapy.  B cell depletion has been shown to be an effective treatment of T 
cell mediated autoimmune diseases such as RA and SLE, independent of circulating 
auto-antibody levels, indicating a role for B effector cells in the regulation of the T cell 
mediated immune response111-114,116.  These findings highlight an important and 
previously unknown facet of B cell mediated immunity that deserves further 
investigation. 
 
Transport and metabolism of nutrient molecules into B lymphocytes   
Lymphocyte metabolism is now recognized as a critical regulator of normal lymphocyte 
responses during activation and differentiation (Figure 3).125-128  Resting lymphocytes 
are characterized by a metabolic profile that relies on a combination of glycolysis and 
fatty acid β oxidation, with the majority of ATP generated through the TCA cycle and 
oxidative phosphorylation.  Both T and B cells increase glucose and glutamine uptake 
following activation, adopt a highly glycolytic and glutaminolytic profile, and limit fatty 
acid β oxidation to conserve lipids for membrane expansion during cellular growth.128-133  
Interestingly, although both B and T cells increase glycolysis during activation, T cells 
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are more heavily glycolytic while activated B cells display a balanced increase in oxygen 
consumption and lactate production.134  Together with increased mitochondrial mass this 
suggests a metabolic profile that still relies on TCA cycle activity and oxidative 
phosphorylation, however glycolysis is essential for certain functional activities 
including antibody production.131,134  Metabolic flux profiling has revealed that during 
the first several days following activation B cells utilize glucose-derived carbon and 
subsequently switch to preferentially utilize glutamine as a carbon source during the 
antibody production period.135  It is possible that these two metabolites have different 
roles during the timeline of the B cell response, a theory that this thesis in part seeks to 
investigate. 
 
  
 
Figure 3. The metabolic phenotypes of nonproliferating and proliferating cells differ.  
Nonproliferating cells utilize glucose, glutamine, and fatty acids equivalently to feed into 
the TCA cycle and generate ATP through oxidative phosphorylation.  Proliferating cells 
primarily utilize glycolysis to generate ATP, and conserve fatty acids for membrane 
expansion while reserving glucose and glutamine as building blocks for the biosynthesis 
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of macromolecules need to support cellular growth and division. 
 
 
In T cells, activation through the TCR and CD28 co-stimulation causes rapid 
upregulation of the high affinity glucose transporter, Glut1, in a PI3K and mTORC1 
dependent manner.136-138  This transporter has also been observed to be upregulated in B 
cells following BCR crosslinking, and is PI3K dependent but only partially inhibited 
rapamycin treatment.131  Glucose uptake and glycolysis are also upregulated during B 
and T cell activation, and in B cells have been shown similarly to Glut1 expression to be 
PI3K dependent and partly mTORC1 dependent.131,137  Glycolytic activity is associated 
with increased inflammatory potential, and is highest in pro-inflammatory Th17 and Th1 
subsets, and lower in regulatory T cells.138-141  Increased glycolysis is additionally 
correlated to Glut1 expression in these cells, and transgenic Glut1 expression in T cells 
leads to hyperactivation with increased IL-2 and IFN-γ production.138  Conversely, 
glucose depletion or inhibition of glycolysis has a suppressive effect on the 
inflammatory T cell response, resulting in decreased proliferation and IFN-γ production.  
In B cells, inhibition of glycolysis is also functionally limiting, resulting in decreased 
antibody secretion both in vitro and in vivo.133,134 Glut1 is believed to be essential for 
glucose import in both T and B lymphocytes as Glut1 knockout studies have shown 
defects in activation similar to those observed during glucose depletion or inhibition of 
glycolysis.142 
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Figure 4.  Glucose can be metabolized to feed into de novo lipid biosynthesis pathways, 
adapted from (145) (permission not required for reprint).  Glucose that has undergone 
glycolysis to generate pyruvate can enter the TCA cycle as acetyl-coA.  Following 
conversion to citrate, and transport back into the cytoplasm, it can then be converted 
back to acetyl-coA by ATP citrate lyase and utilized for the synthesis of fatty acids, 
phospholipids, and cholesterol.143 
 
Once imported, glucose can be utilized as a carbon source for amino acid and 
phospholipid synthesis in addition to the generation of ATP and NADH (Figure 4).45,144-
148  In B cells, glucose has been shown to contribute to de novo lipid synthesis in an 
ATP-citrate lyase (ACLY) dependent mechanism.133  In this process, glucose is 
metabolized through glycolysis to produce 2 molecules of pyruvate.  Pyruvate then 
enters the TCA cycle in the mitochondria and is converted to acetyl-CoA by pyruvate 
dehydrogenase complex (PDH), then further condensed with oxaloacetate to produce 
citrate by citrate synthase.  Citrate then reenters the cytoplasm and is converted to acetyl-
CoA (releasing oxaloacetate) by ACLY, and can act as a carbon source for the 
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biosynthesis of fatty acids and cholesterol through multistep metabolic reactions (Figure 
4).149-152  
Maintenance of glucose levels in proliferating cells is also critical to regulate 
AMPK activity.  When ATP levels drop due to low intracellular glucose, AMPK 
becomes activated and negatively signals through mTORC1 to inhibit cellular growth 
until ATP levels can be restored.153-155  Interestingly, in T cells glutamine can act as an 
alternative fuel when glucose levels are limiting and provide metabolic intermediates 
and ATP generation through an alternative metabolic phenotype.129  
 
Transport and metabolism of L-glutamine in B & T lymphocytes 
Lymphocytes in particular have been observed to rapidly increase glutamine 
import during the initial growth phase of activation, and are dependent on an 
extracellular supply of the amino acid to undergo an appropriate activation 
response.45,156,157 Glutamine uptake and metabolism have recently been characterized in 
T cells, however, virtually nothing is known about amino acid transport in B cells.  This 
glutamine addiction has also been observed in several cancer cell types, and as such a 
recent interest in pathways of glutamine metabolism in proliferating cells has 
emerged.158,159 
Glutamine metabolism begins with the import into the cell through one of several 
high affinity transporters.  Transporters of glutamine include SN1 and SN2 of system N, 
ATA1 and ATA2 of system A, and ASCT2 of system ASC.160,161  In T lymphocytes, 
ASCT2 has been demonstrated to be an important importer of glutamine; ASCT2 
knockout mice display defects in differentiation of activated T cells into certain effector 
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subtypes, as well as decreased total numbers of B cells in the periphery, indicating that 
this transporter is likely important for B cell regulation as well.162,163 
Following uptake, glutamine can be immediately transported back out of the cell 
by transporters such as LAT1.  This allows the import of other essential amino acids 
(EAAs) by antiport, which in turn activate mammalian Target Of Rapamycin Complex 
(mTORC), a key regulator of cellular growth.162,164,165 One of the initial steps in 
metabolizing glutamine is removal of the γ-nitrogen for incorporation into newly 
synthesized macromolecule precursors (Figure 5).  Glutamine is an obligatory nitrogen 
donor for nucleotide synthesis of both purines and pyrimidines and is consequently 
indispensable for the production of new nucleotides needed for cell 
proliferation.149,158,166,167 This could suggest that cells deprived of glutamine are unable 
to proliferate due to the unavailability of nucleotides to synthesize new DNA during S 
phase.  Studies have shown, however, that glutamine utilization rate in proliferating cells 
greatly exceeds nucleic acid synthesis, indicating that there are other pathways requiring 
nitrogen or carbon from glutamine.168,169 The γ-nitrogen group is also required for the 
rate-limiting step in the hexosamine biosynthetic pathway, catalyzed by 
glutamine:fructose-6-phosphate amidotransferase.170,171  This reaction forms 
glucosamine-6-phosphate, a precursor for N-linked and O-linked glycosylation reactions 
that are necessary for protein modification. Inhibition of these reactions can impair the 
ability of proteins to participate in cell signaling, and thereby inhibit cellular growth.172  
Removal of the γ-nitrogen can also produce ammonia and glutamate, when 
catalyzed by glutaminase (GLS).  GLS is expressed at high levels in most proliferating 
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cells, including lymphocytes, and is induced by the transcription factor c-myc.157,173 
High levels of GLS enable cells to rapidly generate glutamate from glutamine, and it is 
glutamate that acts as the substrate for reactions utilizing the carbon skeleton and α-
nitrogen of glutamine.167 
The carbon skeleton is mainly utilized via α-ketoglutarate generated from 
glutamate by either glutamate dehydrogenase or transamination.  The α-nitrogen can be 
used in the synthesis of alanine or aspartate by transamination reactions catalyzed by 
alanine aminotransferase and aspartate aminotransferase.169 Alanine is primarily used in 
protein synthesis, and only accounts for about 3% of the α-nitrogen use in lymphocytes.  
Aspartate transaminase is much more active, possibly because of the more varied uses of 
the amino acid in protein and nucleotide synthesis, as well as electron transfer reactions 
via the malate-aspartate shuttle.42  
 
 
Figure 5. Pathways of glutamine metabolism, adapted and reprinted with permission 
19		
from (176).  Reactions utilizing the α-nitrogen are depicted in green; reactions utilizing 
the γ-nitrogen are depicted in orange, reactions utilizing glutamine derived carbon are 
depicted in pink, and energy generated from the metabolism of glutamine is depicted in 
blue.174 
 
Glutamate can also be used in the synthesis of GSH, a major cellular antioxidant 
that serves as a redox buffer against oxidative stress. Proliferating cells require adequate 
amounts of GSH to resist the oxidative stress generated by rapid metabolism.175 
Glutamate is one of three amino acids used in GSH synthesis, along with cysteine and 
glycine, and is thus necessary for synthesis of the antioxidant.  High intracellular 
glutamate levels are also necessary for the import of cystine, the limiting substrate for 
GSH synthesis, by the Xc− antiporter.  This transporter exports glutamate in exchange for 
cystine, which is then converted to cysteine inside the cell and used in GSH 
production.158 
The α-ketoglutarate produced by the transamination reaction described above 
can be used for oxidation of glutamine's carbon skeleton in the mitochondria, via the 
TCA cycle.  This is a key metabolic fate of glutamine in several proliferating cell types, 
including T lymphocytes and lymphoma cells, and can be a major source of cellular 
energy.146,157,158,176 Glutamine carbon can be oxidized to completion by exit from the 
TCA cycle as malate, followed by conversion to pyruvate and then acetyl-CoA, which 
can then reenter the cycle.  Alternatively, pyruvate can be converted to lactate and 
secreted from the cell.  This has been observed in tumor cell lines, and is referred to as 
“glutaminolysis”, because of its parallels to the incomplete oxidation of glucose 
observed in the glycolytic phenotype of cancer cells.159,177 Conversion of glutamine 
carbon to pyruvate by malic enzyme is also a source of NADPH, a required electron 
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donor for several metabolic reactions.  In addition to ATP generation, this is another 
potential benefit oxidizing glutamine carbon through the TCA cycle.158 
As an alternative to complete cycling through the TCA cycle as a means to 
produce citrate from glutamine, reductive carboxylation of α-ketoglutarate to isocitrate 
can occur in the mitochondria, catalyzed by isocitrate dehydrogenase 1 (IDH1), or the 
cytosol, catalyzed by IDH2. This provides a shortcut for glutamine carbon to be 
converted to acetyl-coA and utilized in de novo lipid synthesis, which is necessary 
during cellular growth.  In some glutamine addicted proliferating cells, glutamine has 
been discovered to actually contribute the majority of the carbons for lipid synthesis, 
while glucose is metabolized through glycolysis and eventually secreted from the cell as 
lactate.178 
An additional crucial role for L-glutamine derived α-ketoglutarate that has been 
established in proliferating tumor cells is to function as a substrate for the epigenetic 
modifying enzymes JHDM and TET.  In these reactions, α-KG serves as an obligate 
methyl group acceptor during the demethylation reactions of 5-methyl-cytosine of DNA 
by TET enzymes, or during histone demethylation by JHDM.179-182  In cancer cells, α-
KG can be competitively inhibited by the onco-metabolite 2-hydroxy-glutarate (2HG), 
an analog that is produced by mutant IDH isoforms that binds the active site of these 
enzymes but cannot act as a methyl acceptor.183-185  This has been observed to affect 
epigenetic reprogramming, causing cancer cells to enter a de-differentiated state.  
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mTOR signaling and regulation of lymphocyte responses 
Signaling through the mTOR pathway has been studied extensively in 
lymphocytes, and is known to be essential for both B and T lymphocyte responses.136,186-
188  Emerging evidence suggests that an integral component of mTOR activity during 
lymphocyte responses is the coordination of cellular growth and metabolic 
reprogramming.189-191  The mTOR serine/threonine kinase functions in mammals as a 
part of two distinct multi-protein complexes, mTORC1 and mTORC2, characterized by 
differences in activity and protein components (Figure 6).187,192   mTORC1 is comprised 
of the mTOR kinase along with the proteins mLST8, Deptor, PRAS40, and most 
distinctively Raptor, making it susceptible to inhibition by rapamycin.192-194  mTORC2 
also contains mTOR kinase as the catalytic subunit, in addition to mLST8, DEPTOR, 
Sin1, Protor1/2, and the characteristic subunit Rictor, and is significantly less sensitive to 
rapamycin treatment, with inhibition only reported by prolonged or high doses in certain 
cell types.192,195,196  Both complexes are active as downstream effectors of the PI3K 
signaling pathway, and in B cells are turned on in response to mitogenic signals or BCR 
crosslinking.197   
 
         
Figure 6. The proteins that make up mammalian target of rapamycin complex 1 
(mTORC1) and 2 (mTORCS2), adapted from (189) (permission for reprint not 
required).187 
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the FRB is the kinase domain responsible for
mTOR’s serine/threonine kinase activity and
also the binding site for mTOR kinase–specific
inhibitors. The C terminus consists of the
FATC domain that is believed to play a role in
maintaining structural integrity. In mammals,
mTOR is encoded as a single gene product.
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(mTORC1) and mTORC2 (11). mTORC1 is
composed of regulatory-associated protein of
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Figure 2
Structure of the mTOR signaling complex. (a) mTOR is an evolutionarily conserved 289-kDa
serine/threo ine protein kinase that is composed of two N-terminal HEAT (huntingtin, elongation factor 3,
subunit of PP2A, and TOR) domains, which mediate protein-protein interactions, adjacent to a FRAP,
ATM, and TRRAP (FAT) domain. The FRB domain is where the small 12-kDa FK506-binding protein
(FKBP12) bound to the macrolide drug rapamycin binds to mTOR to inhibit its activity. The mTOR kinase
catalytic domain lies C-terminal to the FRB site, and this is where mTOR kinase inhibitors bind. The
carboxy FAT (FATC) domain maintains the structural integrity of this large protein kinase. (b) mTOR
associates with two distinct sets of adapter proteins to form two intracellular signaling complexes with
unique substrate specificity. The TORC1 signaling complex is composed of the regulatory-associated
protein of mTOR (RAPTOR) and mammalian lethal with Sec13 protein 8 (mLST8), which are both adapter
proteins that mediate protein-protein interactions via their WD-40 domains. The proline-rich Akt substrate
40 kDa (PRAS40) and DEP domain–containing mTOR-interacting protein (DEPTOR) inhibit mTORC1
activity. The mTORC2 complex can also associate with DEPTOR and mLST8, but this complex is
distinguished by the adapter protein RAPTOR-independent companion of TOR (RICTOR) and protein
observed with RICTOR (PROTOR). Another unique component of mTORC2 is mSIN1, which contains a
pleckstrin homology domain that is thought to target TORC2 to the membrane, where it can activate
myristoylated Akt.
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mTORC2 activity has been less well characterized than mTORC1 in 
lymphocytes, however it’s functions in growth and downstream effectors appear to be 
significantly different.  mTORC2 also acts downstream of PI3K, however detailed 
information on the mechanisms of activation and regulation is yet to be elucidated.  
Downstream targets include AKT, SGK1, and PKC-α, with AKT being the most 
extensively studied.189,198,199  Key roles of mTORC2 include regulation of cell 
metabolism through AKT, as well as cytoskeletal rearrangement.192,200  One of the most 
important functions of mTORC2 in B cells is the phosphorylation of the FOXO 
transcriptional repressor, promoting removal of FOXO and subsequent degradation in 
the cytoplasm, thus allowing cell cycle entry to proceed.201  mTORC2 also has a role in 
effector differentiation of activated lymphocytes; in a RICTOR knockout mouse model, 
activated CD4+ T cells failed to undergo differentiation to the Th2 subset under 
polarizing conditions.196  In B cells, mTORC2 deletion was found to upregulate c-Myc, 
resulting in E2F1 downregulation and increased apoptosis, revealing a new mechanism 
by which mTORC2 regulates cell survival.202 
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Figure 7. Pathways involved in mTORC1 regulation, adapted from (205) (permission 
for reprint not required).  mTORC1 acts downstream of the PI3K/AKT pathway.  
Negative regulation by TSC1/TSC2 of Rheb inactivates mTORC1.  When extracellular 
signals activate the PI3K/AKT pathway, TSC1/TSC2 releases Rheb, thus activating 
mTORC1 to phosphorylate downstream targets such as S6, and promote cell growth and 
proliferation.203 
 
Quiescent T and B cells typically exhibit very low levels of mTORC1 activity, 
however it is rapidly induced following lymphocyte stimulation, with phosphorylation of 
downstream targets appearing as early as 30 minutes following receptor crosslinking.186  
Unlike mTORC2, regulatory mechanisms impacting mTORC1 activation are well 
understood, and although primarily elucidated in non-immune cell types, some have 
been demonstrated to operate in T cells.  mTORC1 activity is inhibited by the tuberous 
sclerosis 1/2  (TSC1/TCS2) complex, a heterodimeric GTP-ase activating protein 
(GAP), downstream of PI3K/Akt (Figure 7).192  PI3K/Akt inactivates TSC1/TSC2, 
releasing Ras homolog enriched in brain (Rheb), a small GTP-ase that promotes 
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mTORC1 activity.  When active, the GAP activity of TSC1/TSC2 regulates the GTP 
bound state of Rheb, converting it to the inactive GDP bound state.   TSC1/TSC2 are 
also regulated by AMPK; when ATP levels in the cell are low AMPK phosphorylates 
and activates the TSC complex to promote GAP activity and Rheb inhibition.  The 
downstream targets of mTORC1 kinase activity are also well studied.  Activated 
mTORC1 initiates phosphorylation of S6 kinase, 4EBP1, and several other downstream 
targets, culminating in transcriptional activation of genes involved in cellular growth, 
glycolysis, lipid synthesis, and inhibition of cellular autophagy.  As these downstream 
targets are strictly dependent on upstream mTORC1 activity for phosphorylation, and 
are not involved in any cross-reactive pathways, they make excellent markers to 
experimentally assess the level of mTORC1 activity in the cell.192 
mTORC1 has been demonstrated in several cell types to be regulated by amino 
acid availability through a complex mechanism.162-165   In a mechanism initially 
discovered in U2OS cells, import of glutamine through the SLC1A5 (ASCT2) 
transporter was coupled to exchange for leucine through SLC7A5 (LAT1) (Figure 8).164  
This amino acid exchange was required for mTORC1 activity.  Both ASCT2 and LAT1 
knockout studies have independently shown that this exchange also plays a role in 
mTORC1 activity in T cells.162,165  Additionally, intracellular α-KG is essential for the 
activation of mTORC1 in certain cell types.204,205  In these studies, α-KG is required for 
the activity of small Rag-GTPases.   These Rag-GTPases control recruitment of 
mTORC1 to the lysosomal surface where it can interact with and be activated by Rheb, 
although it is unclear if this mechanism is also active in lymphocytes.204  Unlike 
mTORC1, mTORC2 is not known to be regulated by nutrient availability, either amino 
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acids or ATP levels. 
 
 
Figure 8. Glutamine and leucine import through ASCT2 and LAT1 (SLC7a5) are 
coordinated to regulate mTORC1 activity, adapted and reprinted with permission from 
(206). In T cells this mechanism is essential for inflammatory T cell responses.206 
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CHAPTER TWO 
Materials and Methods 
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Reagents and Antibodies 
AffiniPure F(ab′)2 fragment goat anti-mouse IgM was obtained from Jackson 
ImmunoResearch Laboratories (West Grove, PA).  Purified rat anti-mouse CD16/CD32 
(Mouse BD Fc Block) antibody (Ab), PE-conjugated rat anti-CD71 monoclonal antibody 
(mAb), APC-conjugated rat anti- CD86 mAb,  APC-conjugated rat anti-mouse CD19, 
APC-conjugated IgG2a, κ isotype control, and PE-conjugated IgG2a, κ isotype control 
Abs were obtained from BD Pharmingen (San Jose, CA).  Alexa Fluor® 647 conjugated 
rabbit Phospho-S6 Ribosomal Protein (Ser235/236) mAb and rabbit anti-histone H3 
mAb, and rapamycin were obtained from Cell Signaling Technologies (Beverly, MA).  
Alexa Fluor® 488 conjugated rabbit anti-glucose transporter (Glut1) mAb, FITC-
conjugated mouse 5-methylcytosine Ab, and rabbit anti-histone H3 (tri-methyl K9) Ab 
were obtained from Abcam Inc (Cambridge, MA).  Rabbit anti-ASCT2 Ab was obtained 
from Millipore (Billerica, MA).  Alexa Fluor® 488 conjugated goat anti-rabbit IgG was 
obtained from Life Technologies (Carlsbad, CA).  PE-conjugated rat anti-mouse IL-10 
and monensin were from eBioscience (San Diego, CA).  Goat anti-rabbit IgG-HRP Ab 
was obtained from Santa Cruz Biotechnology, Inc (Dallas, TX).    2-(N-(7-Nitrobenz-
2-oxa-1,3-diazol-4-yl)Amino)-2-deoxyglucose (2-NBDG) was obtained from Life 
Technologies.  Gamma-L-glutamyl-p-nitroanilide hydrate was obtained from MP 
Biomedicals (Santa Ana, CA).  Lipopolysaccharide (LPS 0111:B4), 6-diazo-5oxo-L-
norleucine (DON), and di-methyl 2-oxoglutarate were obtained from Sigma Aldrich 
(Natick, MA).  D-α-hydroxyglutaric acid (sodium salt) (2HG) was obtained from 
Cayman Chemical (Ann Arbor, MI).  Compound-9 (C-9) was synthesized by AsisChem 
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Inc. (Watertown, MA). All other reagents, unless noted otherwise, were obtained from 
Fisher Scientific (Pittsburgh, PA). 
 
B Lymphocyte Isolation and Culture 
Male BALB/cJ mice were obtained from the Jackson Laboratory (Bar Harbor, ME).  
Mice were house in the Boston College Animal Care Facility cared for and handled at all 
times in accordance with National Institutes of Health and Boston College Institutional 
Animal Care and Use Committee guidelines.  Splenic B cells from mice at 8–12 weeks 
were isolated and purified by negative selection using a B cell isolation kit, 
MidiMACSTM separator, and LS column (Miltenyi Biotec Inc.).  Small dense B cells 
were isolated via centrifugation through a discontinuous 72:65:50% Percoll gradient.  
Purified B cells were cultured in RPMI 1640 medium (Corning) plus 10% dialyzed fetal 
calf serum (dFCS) (Atlanta Biologicals), 2 mM L-glutamine, 10 mM HEPES, pH 7.4, 50 
µM β-mercaptoethanol, 50 units/ml penicillin, and 50 µg/ml streptomycin.  For 
glutamine free culture conditions, cells were cultured in L-glutamine free RPMI 1640 
medium, plus 10% dFCS, 10mM HEPES, pH 7.4, 50 µM β-mercaptoethanol, 50 
units/ml penicillin, and 50 µg/ml streptomycin.  For glucose free culture conditions, cells 
were cultured in glucose-free RPMI 1640 medium plus 10% dFCS, 2 mM L-glutamine, 
10 mM HEPES, pH 7.4, 50 µM β-mercaptoethanol, 50 units/ml penicillin, and 50 µg/ml 
streptomycin.  B cells were activated in culture by the addition of 10 µg/mL F(ab’)2 
fragments of goat anti-mouse IgM. 
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Cell Size Analysis 
Following stimulation and culture as described in the figure legends, B cells (106 cells) 
were collected, washed in ice-cold staining buffer (PBS containing 2% FCS), and 
evaluated using the Forward Scatter (FSC-A) parameter on a BD FACSCanto flow 
cytometer.  Alternatively, to obtain quantitative measurements of average cell volume or 
cell diameter, cells were treated as described and analyzed using the Millipore Scepter 
2.0 cell counter with 40 micron sensors. 
 
Cell Lysate Preparation and Western Blotting 
For AMPK and P-S6 analysis, following stimulation and culture under conditions 
specified in the figure legends, B cells (107 cells) were collected, washed in PBS, and 
solubilized in Triton X-100 lysis buffer (20 mM Tris, pH 7.4, 100 mM NaCl, 0.1% 
Triton X-100) containing protease inhibitor cocktail, Phospho-Stop Phosphatase 
inhibitor cocktail, 1 µM PMSF, and 1 mM DTT for 20 minutes on ice with gentle 
mixing.  Insoluble debris was removed by centrifugation at 14,000 xg for 20 minutes at 4 
°C.  For total Histone H3 and H3me3K9 analysis, following stimulation and culture 
under conditions specified in the figure legends, B cells (107 cells) were collected, 
washed in PBS, and solubilized in RIPA lysis buffer (10 mM Tris-Cl, pH 8.0, 1 mM 
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, and 
140 mM NaCl) containing protease inhibitor cocktail, 1 µM PMSF, and 1 mM DTT for 
20 minutes on ice with gentle mixing.  Insoluble debris was removed by centrifugation at 
14,000 xg for 20 minutes at 4 °C.  Total cellular protein was quantified using the BioRad 
Protein Assay, and equal amounts of protein were loaded and separated on a 10% 
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(AMPK and S6) or 15% (H3 and H3me3K9) polyacrylamide SDS gel following the 
addition of 2x SDS sample buffer and 10 minutes at 100 °C.  Protein was then 
transferred to an Immobilon-PVDF membrane, and blocked in TBS-T (20 mM Tris [pH 
7.6], 137 mM NaCl, and 0.05% Tween 20) containing 5% Bovine Serum Albumin 
(AMPK and S6) or 5% dry nonfat milk (H3 and H3me3K9) for 60 min at room 
temperature.   The membrane was then rinsed and incubated overnight at 4 °C with the 
described primary Ab at the manufacturer’s recommended dilution.  The membrane was 
washed 4x for 5 min in TBS-T and incubated with a 1:25000 dilution of anti-rabbit HRP 
conjugated secondary Ab, washed an addition 4x for 5 min and developed by ECL and 
autoradiography film. 
Cell Viability Analysis 
To analyze the percentage of viable cells, 106 B cells were collected, washed in ice cold 
PBS, and resuspended in PBS containing 50 µg/ml propidium iodide for 30 min (37 °C) 
and analyzed by flow cytometry using a FACSCanto cytometer.  Cells that stained 
positive for propidium idodide were excluded from the viable population. 
Cell Cycle Measurements and Protein Detection 
B cells (106 cells) were collected, washed in ice-cold staining buffer (PBS containing 2% 
FCS), and resuspended in PBS containing 0.1% Triton X-100, 50 µg/ml propidium 
iodide, and 50 µg/ml RNase A for 30 min (37 °C). DNA content was measured by flow 
cytometry using a FACSCanto cytometer.  FITC staining for total intracellular protein 
content was carried out with 106 B cells that were washed with ice-cold staining buffer 
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and then fixed and permeabilized with the Cytofix/Cytoperm kit according to the 
manufacturer's instructions; cells were stained with FITC and analyzed by flow 
cytometry. Cell size was analyzed using flow cytometry by measuring the mean forward 
scatter of 106  B cells that were collected, washed in ice-cold staining buffer, and 
resuspended in staining buffer.  For S6-pS235/236 staining, 106  B cells were collected, 
washed in ice-cold staining buffer and then incubated in 100 µl of staining buffer 
containing 2 µl of rat anti-mouse CD16/CD32 for 20 min.  Cells were then fixed and 
permeabilized using the Cytofix/Cytoperm kit according to the manufacturer's 
instructions and stained with Alexa Fluor® 647 conjugated rabbit anti-S6-pS235/236 for 
60 min (4 °C). Cells were washed three times in staining buffer and analyzed by flow 
cytometry.  B lymphocyte-induced maturation protein-1 (Blimp-1) staining was carried 
out with 106 splenic B cells that were washed with ice-cold staining buffer and then 
fixed and permeabilized with the transcription factor buffer set according to the 
manufacturer's instructions (BD Pharmingen); cells were stained with Alexa Fluor 647-
conjugated rat anti-mouse Blimp-1 (BD Biosciences) and analyzed by flow cytometry.  
 
Surface Marker Staining and Flow Cytometry  
For CD86 staining, 106 B cells were washed with ice-cold staining buffer (PBS 
containing 2% FCS,) and then incubated in 100 µl of staining buffer containing 2 µl of 
rat anti-mouse CD16/CD32 Ab for 20 min. Cells were then stained with APC-
conjugated rat anti-mouse CD86 Ab or APC-conjugated rat IgG2a, κ isotype for 60 min 
(4 °C). Cells were washed three times with staining buffer and analyzed by flow 
cytometry.  For CD71 staining, 106 B cells were washed with ice-cold staining buffer 
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and then incubated in 100 µl of staining buffer containing 2 µl of rat anti-mouse 
CD16/CD32 Ab for 20 min. Cells were then stained with PE-conjugated rat anti-mouse 
CD71 Ab or PE-conjugated rat IgG2a, κ isotype control for 60 min (4 °C). Cells were 
washed three times with staining buffer and analyzed by flow cytometry.  For CD138 
surface staining, 106 splenic B cells were washed with ice-cold staining buffer (PBS 
containing 1% FCS, 0.1% NaN3) and then incubated with 100 µl of staining buffer 
containing 1.5 µl of rat anti-mouse CD15/CD32 Ab (BD Biosciences) for 20 min. Cells 
were then stained with PE-conjugated rat anti-mouse CD138 Ab or PE-conjugated rat 
IgG2a, κ isotype control (BD Biosciences) for 45 min (4 °C). Cells were washed three 
times with staining buffer and analyzed by flow cytometry.   
 
Glutamine Transport Assay 
B lymphocytes were washed and resuspended at 4.0 x 107 cells/ml in choline-Krebs-
Ringer (choline-KRP) buffer (119 mM choline chloride, 5.9 mM KCl, 1.2 mM MgSO4, 
1.2 mM KHCO3, 5.6 mM glucose, 0.5 mM CaCl2, 25 mM choline bicarbonate, 0.15% 
(w/v) bovine serum albumin (BSA)) and incubated for 30 min at 37°C in order to deplete 
intracellular sodium and amino acid pools.  Cells were then collected by centrifugation 
and resuspended in choline-KRP at 4.0 x 107 cells/ml. Transport was initiated by mixing 
200 ml of B cells with 200 ml of choline-KRR buffer plus 4 mCi/ml [3H] glutamine or 
200 ml of sodium-KRP buffer (119 mM NaCl, 5.9 mM KCl, 1.2 mM MgSO4, 1.2 mM 
KHCO3, 5.6 mM glucose, 0.5 mM CaCl2, 25, mM choline bicarbonate, 0.15% (w/v) 
BSA) plus 4 mCi/ml [3H] glutamine.  After the appropriate time, 50 ml of transport 
buffer plus cells was loaded on to a prepared gradient containing a 200 ml 
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bromododecane upper layer and a 40 ml 20% perchloric acid lower layer and centrifuged 
at 14,000 x g for 2 min in a fixed angle microcentrifuge.  The two upper layers were 
removed and discarded, while the perchloric acid layer was placed into a liquid 
scintillation vial containing aqueous-sample-compatible liquid scintillation cocktail.  
Samples were quantitated using liquid scintillation spectrophotometry. To determine the 
contribution of system A to Na+-dependent [3H] glutamine uptake, glutamine transport 
was carried out in the absence and presence of the system A specific nonmetabolizable 
substrate methylaminoisobutryic acid (meth-AIB) at a concentration of 1 mM.  In order 
to determine the contribution of the high affinity System ASCT2 to Na+-dependent 
glutamine transport, [3H] glutamine uptake was carried out in the absence and presence 
of 1 mM threonine or 1 mM leucine. ASCT2 exhibits specificity to a wide panel of 
zwitterionic amino acids such as threonine, serine and to a lesser degree bulky/branch-
chain amino acids such as leucine and valine.  
 
Nutrient Transporter Detection 
For ASCT2 expression, 106 B cells were collected, washed in ice-cold staining buffer 
and then incubated in 100 µl of staining buffer containing 2 µl of rat anti-mouse 
CD16/CD32 Ab for 20 min.  Cells were then fixed in 4% paraformaldehyde and 
permeabilized in PBS containing 0.1% Saponin and stained with rabbit anti-ASCT2 Ab 
for 60 min (4 °C).  Cells were washed three times in ice-cold staining buffer and 
incubated in Alexa Fluor® 488 conjugated goat anti-rabbit Ab for 45 min (4 °C).  Cells 
were washed three times in staining buffer and analyzed by flow cytometry.  For Glut1 
expression, 106 B cells were collected, washed in ice-cold staining buffer and then 
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incubated in 100 µl of staining buffer containing 2 µl of rat anti-mouse CD16/CD32 Ab 
for 20 min.  Cells were then fixed in 4% paraformaldehyde and permeabilized in PBS 
containing 0.1% Saponin and stained with Alexa Fluor® 488-conjugated rabbit anti-
Glut1 mAb for 60 min (4 °C).  Cells were washed three times in staining buffer and 
analyzed by flow cytometry.   
 
qPCR  
cDNA was isolated using the µMACS One-step cDNA kit and thermoMACS separator 
(Miltenyi Biotec).  Integrated DNA Technologies PrimeTime® qPCR primers for mouse 
Slc1A5 (ASCT2) and β-2-micoglobulin (β2m) consisting of the following sequences:   
β2m forward, 5’-TTCAAATGAATCTTCAGAGCATCA-3’;  
β2m reverse, 5’-TCTATATCCTGGCTCACACTGA-3’;  
Slc1A5 forward, 5’-ACATGACTTGTCTTTGGGTTCA-3’;  
Slc1A5 reverse, 5’-GCTGGATTCCTTTCTAGATCTCG-3’.   
The relative quantities of ASCT2 expression were calculated and normalized to β2m 
expression using the ΔΔCt values for each sample.   
 
Nutrient Uptake Measurements 
For glucose uptake was measurements, 106 activated B cells were washed in PBS and 
resuspended in glucose-free RPMI and incubated for 4 hours.  150 µg/mL of the 
fluorescent glucose analog 2-NBDG was added and cells were incubated for an 
additional 30 minutes.  Cells were then washed in PBS and analyzed by flow cytometry. 
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Endoplasmic Reticulum Staining for FACS and Microscopy 
For ER-TrackerTM staining by flow cytometry, 106 splenic B cells were washed with ice-
cold PBS. Cells were then incubated with 1 µM ER-TrackerTM dye for 30 min (37 °C), 
washed three times with PBS, and analyzed by flow cytometry. In all experiments, 
analysis was carried out on the gated viable cell population. Flow cytometry was carried 
with a BD FACSCanto cytometer, and the data were analyzed by FACSDiva software 
(BD Biosciences).  B cells (1 × 106) were collected and washed with HBSS containing 
2% FCS. Cells were then incubated with 5 mM  ER-Tracker GreenTM dye (Invitrogen) in 
HBSS containing 2% FCS for 30 min. B cells were washed with HBSS containing 2% 
FCS and resuspended in RPMI 1640 medium, transferred to chambered coverglass and 
analyzed by confocal microscopy. 
 
Antigen Receptor Endocytosis Staining 
For analysis of antigen receptor endocytosis, 106 splenic B cells were washed 
with ice-cold PBS.  Unstimulated B cells were incubated with FITC conjugated goat 
anti-mouse IgM on ice for 10 minutes.  Cells were washed in ice cold staining buffer to 
remove excess antibody, and incubated at 37 °C for indicated time periods.  Cells were 
then fixed and permeabilized with the BD Cytofix/Cytoperm kit according to the 
manufacturer's instructions, and stained with APC conjugated rabbit anti-mouse LAMP-
1 for 60 minutes on ice.  Cells were then washed 3 times in ice-cold staining buffer and 
analyzed by confocal microscopy for colocalization of antigen receptor and LAMP-1. 
Cells in media were mounted in ProLong Gold (Life Technologies, P36930) and imaged 
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with an APOCHROMAT 40X, 1.4 NA objective with a 3.0-X optical zoom for all 
images on a Zeiss 700 LSCM.	
 
Analysis of IL-10 Production 
Intracellular analysis of IL-10 production was carried out according to published 
methods.207  Purified B cells were cultured at a density of 2 x 106 cells/ml in complete 
media, media lacking glutamine, or complete media containing 5 mM GPNA and 
stimulated with 10 µg/ml LPS for 48 hours.  For the final 5 hours of stimulation, cells 
were treated with 50 ng/ml PMA, 500 ng/ml Ionomycin, and 2 µM monensisn. 106  B 
cells were collected, washed in ice-cold staining buffer and then incubated in 100 µl of 
staining buffer containing 2 µl of rat anti-mouse CD16/CD32 for 20 min, followed by 
staining with APC-conjugated rat anti-mouse CD19.  Cells were then fixed and 
permeabilized using the Cytofix/Cytoperm kit according to the manufacturer's 
instructions and stained with PE conjugated rat anti-mouse IL-10 for 60 min (4 °C). 
Cells were washed three times in staining buffer and analyzed by flow cytometry.  To 
quantitate secreted IL-10, isolated B cells were cultured at a density of 4 x 105 cells in 
0.2 ml of indicated media in a 96 well flat-bottom plate and stimulated with 10 µg/ml 
LPS for 72 hours.  Cell culture supernatant was analyzed for IL-10 concentration using 
the BD Pharmingen IL-10 OptEIA ELISA kit according to the manufacturer’s protocol.  
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CHAPTER THREE 
Differential requirements for glutamine and glucose in B cell activation  
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RESULTS 
Extracellular L-glutamine and glucose are dispensable for induction of very early 
activation surface markers 
I initially sought to characterize nutrient requirements during very early stages of 
B cell activation.   Early evidence indicates the importance of extracellular L-glutamine 
and glucose during lymphocyte activation, however it has not been established whether 
these nutrients are interchangeable, or what the specific role of each nutrient is during 
the B cell response.42,73,149  To determine the nutrient requirements we compared the 
expression of activation induced surface markers and growth related changes in B cells 
cultured in nutrient replete (complete) media to B cells cultured in the absence of L-
glutamine or glucose.  We chose to focus our analysis on expression changes in 
molecules that are known to have a functional role during B cell activation.  Expression 
of CD86, the T cell costimulatory molecule B7-2, was upregulated in B cells stimulated 
with 10 µg/mL (Fab’)2 anti-mouse IgM (anti-Ig) for 24 hours as compared to the 
expression in resting cells (Figure 1).  This upregulation was unaffected by the 
availability of extracellular L-glutamine or glucose.   CD86 is a very early surface 
marker for activation of B cells, with maximal upregulation induced 12-24 hours 
following B cell receptor (BCR) crosslinking.69   
 
Extracellular L-glutamine but not glucose is required for induction of later activation 
surface marker CD71 and growth related activation events 
The transferrin receptor, CD71, is an early activation marker with maximal 
upregulation occurring at approximately 24 hours after BCR crosslinking.  CD71 is 
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expressed on all proliferating cells and is essential for the import of iron via 
transferrin.71,73  Surface CD71 was also increased following 24 hour stimulation with 
anti-Ig as compared to resting, non-stimulated B cells in both nutrient replete conditions 
and glucose depleted conditions, although to a lesser extent.  Cells stimulated in L-
glutamine depleted conditions did not exhibit significant CD71 upregulation as 
compared to resting cells (Figure 2).  In addition to changes in expression of cell surface 
markers, activated B cells also undergo growth related changes, including increased cell 
size and upregulation of protein synthesis, later followed by S phase entry and DNA 
synthesis.  Following stimulation with anti-Ig, both B cell populations cultured in 
complete media and in the absence of glucose were able to increase cell size, as 
determined by both forward scatter and average cell diameter, whereas cells stimulated 
in the absence of L-glutamine did not increase cell size as compared to naïve cells 
(Figure 3a, 3b).  One of the growth events associated with B cell activation is an increase 
in protein synthesis.  Resting B cells are transcriptionally and translationally inert, 
however both mRNA and protein synthesis are elevated following BCR crosslinking.208  
As both glucose and glutamine can be metabolized to produce amino acids such as 
glycine, serine, cysteine, alanine, asparagine, and proline, which may be essential for the 
synthesis of new proteins, I sought to examine whether intracellular protein levels would 
be affected by glucose or glutamine depletion.  A simple and easy method for roughly 
quantifying intracellular protein is to permeabilize cells and stain with fluorescein 
isothiocyanate (FITC). FITC is widely used to covalently label proteins via reaction with 
the terminal amino groups and primary amines of proteins.209,210 Total intracellular 
protein content was measured by intracellular FITC labeling, and was shown to increase 
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following stimulation in cells cultured in complete media.  The increase in total protein 
content was reduced in L-glutamine deprived cells, and to a lesser extent in glucose 
deprived cells, however was still elevated as compared to naïve cells (Figure 4).   
 
Extracellular L-glutamine does not contribute to cell viability 
 B cells stimulated with anti-Ig alone rapidly undergo apoptosis and typically lose 
50% of viable cells after just 24 hours, with even lower viability during extended times 
in culture.74  To examine whether nutrient availability had an impact on cell survival 
following BCR crosslinking, cells were analyzed by propidium iodide (PI) exclusion 
assay after 24 hours of culture in complete media, glutamine depleted media, or glucose 
depleted media and compared to naïve cells cultured for the same time period.  PI is a 
DNA intercalating agent that only fluoresces when in contact with DNA.  As it is a 
membrane-impermeable dye, it will only be able to enter cells and nuclei that have lost 
membrane integrity as associated with cell death, making it an especially useful tool to 
discriminate live from dead cells by flow cytometry.  Interestingly, although lack of 
extracellular glutamine led to no significant change in cell viability after 24 hours, lack 
of extracellular glucose led to a decrease in viability compared to cells in complete 
media (Figure 5a).  To analyze time-dependent changes in viability, a time course assay 
was performed to compare viability of glutamine deprived, complete media, and 
unstimulated / naïve cells after 4, 8, 12, and 24 hours in culture.  Again, B cells 
stimulated in glutamine depleted media exhibited only a marginal decrease in cell 
viability during the 24 hour period following BCR crosslinking (Figure 5b).   
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Extracellular L-glutamine is required for cell cycle entry; cell cycle entry is only 
slightly impaired in the absence of extracellular glucose 
Activated B cells in culture begin entry into S phase approximately 48 hours after 
stimulation, and previous studies have shown an essential requirement for L-glutamine 
in order for lymphocytes to undergo DNA synthesis.149,166,211  To determine whether 
glucose is also essential for this process, we examined intracellular DNA content of B 
cells 48 hours after anti-Ig stimulation by PI staining and flow cytometric analysis.  We 
found that glucose deprived cells were still able to increase DNA content, although to a 
lesser extant than cells cultured in complete media.  L-glutamine deprived cells were 
unable to increase DNA content as compared to naïve cells (Figure 6).  Together with 
the growth related differences in glucose and glutamine deprived B cells, these data 
indicate a clear difference between the effects of extracellular L-glutamine and glucose 
on early B cell activation events.  The severe impairment of growth related changes in L-
glutamine deprived cells indicates a block at G1 entry, whereas glucose appears to be 
dispensable for cell cycle entry and progression through S phase. 
 
Increased IL4Rα  expression is dependent on both extracellular L-glutamine and 
glucose 
Having determined distinct requirements for glucose and glutamine during B cell 
activation, I proposed to establish a functional marker that could be used to FACS sort 
and purify cells that had gone through the early activation growth stages that require 
glutamine.  These cells could then be placed back in culture in glutamine depleted media 
to determine whether glutamine was required for early stages only.  In order to sort cells 
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and have them remain viable the marker must be expressed on the cell surface so as not 
to require fixation for staining, and must clearly distinguish between positive and 
negative populations, which ruled out CD71 as a good candidate marker.   Following 
BCR crosslinking, B cells rely on expression of surface receptors for IL4, IL4Rα within 
the first 24 hours.212  IL4Rα recognizes IL-4 and IL-13 and regulates, for example, IgE 
production in B cells.213-215  IL-4 is a pro-survival cytokine released by T cells in 
response to B cell antigen presentation that inhibits BCR crosslinking induced apoptosis 
through signaling through STAT6.132,216  Interestingly, IL4Rα expression has also been 
found to be essential for the differentiation of activated B cells into the B-effector 2 (Be-
2) subtype, characterized by secretion of IL-2, IL-4, and IL-6.106  Differentiation into the 
Be-2 effector type is mediated by obligatory signaling from T cells, including IL4 
secretion.  To determine whether IL4Rα expression was glucose or glutamine 
dependent, naïve splenic B cells were stimulated with 10 µg/mL anti-Ig for 24 hours in 
complete media, media lacking glucose, or media lacking glutamine, and compared to 
naïve cells for IL4Rα expression as analyzed by flow cytometry.  IL4Rα expression was 
maintained but not increased in cells following activation, however this expression was 
decreased by either glucose or glutamine depletion (Figure 7).  Interestingly, although 
this receptor was analyzed during the same timeline as our other early activation 
markers, its expression was equally glucose and glutamine dependent.  This indicates a 
mechanism of induction that is distinct from the growth related events characterized as 
differently affected by glucose or glutamine depletion.   
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Low concentrations of extracellular L-glutamine are sufficient to fully restore early 
activation events 
 Having determined that there are distinct differences between the requirements 
for extracellular glucose and glutamine during the B cell activation, I next sought to 
determine whether these effects were dependent on the concentration of extracellular 
nutrients.  Cell culture media typically contains high concentrations of nutrients well 
beyond concentrations that would be physiologically relevant or typically encountered in 
vivo.129,159  However, early studies in lymphocytes indicated that these high 
concentrations of nutrients were necessary to produce a vigorous proliferation response 
in vitro and therefore were adopted as standard culture media for lymphocyte activation 
in culture.  Standard B cell culture media (RPMI1640) contains 11 mM glucose and 2 
mM glutamine, and typically contains additional supplemented 2 mM glutamine for a 
final concentration of 4 mM glutamine.  To determine the effect of lower concentrations 
of these two nutrients on activation markers and cell cycle entry, splenic B cells were 
stimulated in media containing either 0 mM, 0.5 mM, or 4 mM glutamine, or 0 mM, 1 
mM, or 11 mM glucose.  The 4 mM glutamine media and 11 mM glucose media were 
included to control for potential effects of adding the nutrients back to RPMI media that 
did not initially contain any amount of either glucose or glutamine.  Expression of CD86 
was analyzed by flow cytometry surface staining, and was found to not be detectably 
affected by concentration of either glucose or glutamine (Figure 8).  This correlates with 
the original finding that nutrient depletion did not negatively impact CD86 induction 
following BCR crosslinking.  Although error bars appear large for this experiment, this 
is due to the dim staining, and representative histograms accurately depict that there are 
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no visible differences in expression across the sample conditions.  Surface CD71 
expression was also analyzed by flow cytometry, as its induction had been previously 
found to be glutamine and glucose dependent, with differences in inhibition between the 
two.  Interestingly, CD71 expression was fully restored by low concentrations of 
glutamine, however low concentrations of glucose were not sufficient to restore maximal 
upregulation (Figure 9).  When cell size was analyzed by flow cytometry using the FSC 
parameter, low concentrations of glutamine were again sufficient to fully restore cell size 
increase following anti-Ig stimulation.  Inhibition of cell size increase under glucose 
limiting conditions was minimal even under complete glucose depletion, but appeared to 
be concentration dependent, with cell size increasing more with each increasing glucose 
concentration (Figure 10).  This in combination with the CD71 data suggests that 
glutamine requirement may act in a “threshold” manner, with low concentrations being 
sufficient to fully restore activation events, while glucose associated defects are directly 
regulated by the concentration of glucose.   To analyze cell cycle entry, splenic B cells 
were activated with anti-Ig and the cytokine IL-4 for 48 hours and DNA content was 
analyzed by flow cytometry.  IL-4 was included in the activation media to increase 
viability at the 48 hour time point, as many cells undergo apoptosis by this time point 
when stimulated with anti-Ig alone.  Additionally, IL-4 costimulation increases the total 
percentage of cells that enter S phase, allowing me to better observe any changes in 
percentage associated with nutrient concentration that may have been more difficult with 
very low maximum percentage cell cycle entry.  Similarly to the earlier growth related 
activation events (CD71 and cell size), cell cycle entry was fully restored by low 
concentrations of extracellular glutamine (Figure 11).  In fact, previous studies in total 
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lymphocyte populations indicated that concentrations as low as 0.1 mM glutamine 
restored proliferation and high concentrations of glutamine did not lead to increased 
proliferation.149,166  The results shown here confirm that this finding remains in effect in 
purified B cell populations.  Conversely, cell cycle entry as measured by percentage of 
cells in S phase was dependent on the concentration of glucose, with 0 mM glucose 
resulting in the lowest percentage of S phase cells, and 11 mM glucose resulting in the 
highest.  These findings reveal previously unknown distinctions between the 
requirements for glucose and glutamine during B cell activation.  Altogether, these data 
indicate that the glutamine requirement occurs earlier than the glucose requirement, and 
is indicative of a G1 block, and is a threshold effect with low concentrations being 
sufficient.  Under glucose limiting conditions, although early effects are observed they 
are not as severe as observed under glutamine depletion, and is required in a directly 
concentration dependent manner.   
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FIGURES AND LEGENDS 
Figure 1. Extracellular L-glutamine and glucose are not required for CD86 
upregulation during B cell activation. Naïve B cells were activated with 10 µg/mL 
anti-Ig and cultured in either complete (nutrient replete) media, media lacking glucose, 
or media lacking L-glutamine for 24 hours and compared to naïve cells.  Cells were 
collected and then analyzed by flow cytometry for surface expression of CD86.  Data 
represents analysis of live gated B cells and is expressed as the percentage of cells that 
stained positive for CD86 expression.  The data are representative of 2 independent 
experiments.  Error bars represent standard deviation from the mean.  Shown below are 
representative histograms of CD86 expression for cells cultured in complete media (red), 
media lacking glucose (green), or media lacking L-glutamine (blue) overlaid with 
expression on naïve cells (grey). 
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Figure 2.  Expression of the later activation marker CD71 in response to nutrient 
depletion. Naïve B cells were activated with 10 µg/mL anti-Ig and cultured in either 
complete (nutrient replete) media, media lacking glucose, or media lacking L-glutamine 
for 48 hours and compared to naïve cells.  Cells were collected and then analyzed by 
flow cytometry for surface expression of CD71.  Data represents analysis of live gated B 
cells and is expressed as Mean Fluorescence Intensity (MFI).  The data are 
representative of 3 independent experiments.  Error bars represent standard deviation 
from the mean.  Shown below are representative histograms of CD71 expression for 
cells cultured in complete media (red), media lacking glucose (green), or media lacking 
L-glutamine (blue) overlaid with expression on naïve cells (grey). 
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Figure 3. BCR-mediated cell size increase is inhibited by L-glutamine deprivation. 
Naïve B cells were activated with 10 µg/mL anti-Ig and cultured in either complete 
(nutrient replete) media, media lacking glucose, or media lacking glutamine for 24 or 48 
hours and compared to naïve cells.  A. Cells were analyzed by flow cytometry for cell 
size by mean Forward Scatter (FSC) as described in Materials and Methods, gated on 
live cells.  Data is expressed as Mean FSC.  Results are representative of three 
independent experiments.  Error bars represent standard deviation from the mean.  B. 
Cells were analyzed after 24 or 48 hours for mean cell diameter by the Millipore 
ScepterTM.  The data are represented as mean cell size in µm (Naïve shown in light blue, 
complete media shown in red, 0 mM glucose shown in dark blue, 0 mM glutamine 
shown in green).  
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Figure 4. Intracellular protein content is dependent on extracellular L-glutamine. B 
cells were activated with 10 µg/mL anti-Ig and cultured in either complete (nutrient 
replete) media, media lacking glucose, or media lacking L-glutamine for 24 hours and 
compared to naïve cells.  Cells were collected and stained with FITC as described in the 
Materials and Methods.  Data is expressed as Mean Fluorescence Intensity (MFI).  
Results are representative of 3 independent experiments.  Error bars represent standard 
deviation from the mean.  Shown below are representative histograms of FITC total 
protein staining for cells cultured in complete media (red), media lacking glucose 
(green), or media lacking L-glutamine (blue) overlaid with expression on naïve cells 
(grey). 
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Figure 5. Cell viability is not measurably affected by L-glutamine deprivation. 
Naïve B cells were activated with 10 µg/mL anti-Ig and cultured in either complete 
(nutrient replete) media, media lacking glucose, or media lacking L-glutamine and 
compared to unstimulated naïve cells. Cells were analyzed by flow cytometry for 
viability by PI exclusion. A. Cells were cultured for 24 hours and analyzed for viability. 
Data are expressed as percentage of viable cells from analysis of 10,000 cells.  Results 
are representative of two independent experiments.  B. Cells were analyzed at 4, 8, 12, 
and 24 hours following stimulation (Complete media shown in blue, 0 mM glutamine 
shown in red, unstimulated cells shown in green). Data are expressed as percentage of 
viable cells from analysis of 10,000 cells.  Results are representative of two independent 
experiments.  Error bars represent standard deviation from the mean. 
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Figure 6. Cell cycle progression in the absence of glucose. Naïve B cells were 
activated with 10 µg/mL anti-Ig and cultured in either complete (nutrient replete) media, 
media lacking glucose, or media lacking L-glutamine for 48 hours and compared to 
naïve cells.  Cells were collected and stained for DNA content by PI after fixation, 
permeabilization and RNAse treatment.  Cells were analyzed by flow cytometry; results 
are representative of 3 independent experiments.  Data is represented as the percentage 
of cells in G0/G1 (shown in blue), S (shown in red), and G2/M (shown in green) stages of 
the cell cycle. 
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Figure 7. IL4Ra expression is downregulated in the absence of extracellular glucose 
or L-glutamine.  B cells were activated with 10 µg/mL anti-Ig and cultured in either 
complete (nutrient replete) media, media lacking glucose, or media lacking L-glutamine 
for 24 hours and compared to naïve cells.  Cells were analyzed by flow cytometry for 
surface expression of IL4Ra, gated on live cells.  Data is expressed as Mean 
Fluorescence Intensity (MFI). Results are representative of two independent 
experiments.  Error bars represent standard deviation from the mean. 
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Figure 8. BCR-induced CD86 upregulation is not significantly affected by nutrient 
concentration.  Naïve B cells were activated with 10 µg/mL anti-Ig and cultured in 
media containing 0 mM, 1 mM, or 11 mM glucose, or media containing 0 mM, 0.5 mM, 
or 4 mM L-glutamine for 24 hours and compared to naïve cells.  Cells were analyzed by 
flow cytometry for surface expression of CD86, gated on live cells.  Data is expressed as 
the percentage of cells that stained positive for CD86 expression, results are 
representative of two independent experiments.  Error bars represent standard deviation 
from the mean.  Shown below are representative histograms of CD86 expression at 
different nutrient concentrations (blue) overlaid with expression on naïve cells (grey). 
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Figure 9. Relatively lower concentrations of extracellular L-glutamine are sufficient 
to restore CD71 upregulation.  Naïve B cells were activated with 10 µg/mL anti-Ig and 
cultured in media containing 0 mM, 1 mM, or 11 mM glucose, or media containing 0 
mM, 0.5 mM, or 4 mM L-glutamine for 48 hours and compared to naïve cells.  Cells 
were analyzed by flow cytometry for surface expression of CD71, gated on live cells. 
Data is expressed as Mean Fluorescence Intensity, results are representative of two 
independent experiments.  Error bars represent standard deviation from the mean.  
Shown below are representative histograms of CD71 expression at different nutrient 
concentrations (blue) overlaid with expression on naïve cells (grey). 
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Figure 10. Low concentrations of extracellular L-glutamine are sufficient to restore 
cell size.  Naïve B cells were activated with 10 µg/mL anti-Ig and cultured media 
containing 0 mM, 1 mM, or 11 mM glucose, or media containing 0 mM, 0.5 mM, or 4 
mM L-glutamine for 24 hours and compared to naïve cells.  Cells were analyzed by flow 
cytometry for cell size measure by mean forward scatter, gated on live cells.  Data is 
expressed as Mean Forward Scatter, results are representative of two independent 
experiments.  Error bars represent standard deviation from the mean.  Shown below are 
representative histograms of forward scatter at different nutrient concentrations (blue) 
overlaid with expression on naïve cells (grey).  
65		
Figure 10. 
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Figure 11. Low concentrations of extracellular L-glutamine are sufficient to restore 
cell cycle entry.  B cells were activated with 10 µg/mL anti-Ig and  IL4 and cultured in 
media containing 0 mM, 1 mM, or 11 mM glucose, or media containing 0 mM, 0.5 mM, 
or 4 mM L-glutamine for 48 hours and compared to naïve cells. Cells were cultured for 
48 hours and stained for DNA content by Propidium Iodide after fixation, 
permeabilization and RNAse treatment.  Cells were analyzed by flow cytometry; results 
are representative of two independent experiments, error bars represent standard 
deviation from the mean.  Data is represented as the percentage of cells in G0/G1 (shown 
in blue), S (shown in red), and G2/M (shown in green) stages of the cell cycle. 
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Figure 11.  
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CHAPTER FOUR 
ASCT2 mediated L-glutamine uptake and glutaminolysis are essential for 
mTORC1 activity 
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RESULTS 
Glutamine transport in B cells occurs in a sodium-dependent manner via System ASC 
 Having determined that extracellular L-glutamine is required at a very early stage 
of B cell activation, I next investigated the mechanism by which uptake into the cell is 
achieved.  There are several transporters capable of translocating L-glutamine as a 
substrate, most notable being transporter systems A, L, and ASC.  Systems A and ASC 
are sodium-dependent carriers, while system L is sodium-independent.161,217  To narrow 
down which transport system was primarily responsible for L-glutamine import, L-
glutamine uptake was evaluated in the presence or absence of external sodium.  Splenic 
B cells were cultured with phorbol myristate acetate (PMA) plus ionomycin overnight to 
induce activation.218  For these studies, B cells were stimulated with PMA and 
ionomycin in order to increase the total number of cells stimulated in vitro.218 Uptake of 
[3H] glutamine was measured at 45, 90, 120, and 180 seconds in choline KR buffer with 
or without sodium.  Uptake of L-glutamine occurred in both sodium containing buffer 
and sodium free buffer, however was greater in sodium containing buffer, indicating that 
uptake primarily occurs in a sodium dependent manner (Figure 12).  In order to further 
determine the transport system mainly responsible for L-glutamine uptake, inhibitors 
that act specifically on either system A, L, or ASC were utilized.  
Methylaminoisobutyric acid (MethAIB) is a non-metabolizable transport-specific analog 
inhibitor of system A.219  System ASC is a strict stereoselective transporter with site 
specificity best fitted to threonine.  System L exhibits broad specificity and preferential 
transport of leucine, however it is sodium-independent, and thus is likely not the primary 
mediator of glutamine uptake.217  Glutamine uptake increased 5-fold in cells stimulated 
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with PMA and ionomycin when compared to untreated cells, in agreement with data 
from early studies demonstrating that lymphocyte stimulation induces an increase in 
glutamine consumption.42,149,166  Uptake of glutamine remained high in the presence of 1 
mM MethAIB, demonstrating that system A is not a significant glutamine importer.  
Glutamine uptake decreased 11-fold in the presence of 1 mM threonine, and in the 
presence of 1 mM leucine glutamine uptake decreased 4-fold and was similar to the level 
seen in cells cultured in medium alone (Figure 13).  Although competitive inhibition of 
system L decreased glutamine uptake 4x, this is more likely do to the obligate antiport 
activity of this system.164,220  In exchange for leucine and other amino acids, system L 
transporters will selectively export glutamine from the cell, so a high concentration of 
extracellular leucine would most likely drive heightened export of glutamine.  These 
results, in context with uptake occurring in a primarily sodium dependent manner, 
indicated that system ASC is the primary mediator of glutamine uptake in activated B 
cells.   
 
ASCT2 is upregulated following BCR engagement in a time dependent manner at both 
the mRNA and protein levels 
Within system ASC family, the transporter ASCT2 (Slc1A5) has a high affinity 
for glutamine, and has been shown to be a critical importer of glutamine in activated T 
lymphocytes and lymphoma cell lines.160,217,221-223  To confirm ASCT2 involvement in 
activation associated glutamine uptake, I evaluated whether ASCT2 is upregulated 
following BCR crosslinking. ASCT2 expression was measured at the mRNA level by 
qPCR in samples at 0, 6, 12, 18, and 24 hours in culture with anti-Ig, and expression 
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levels were normalized to β-2 microglobulin (β-2M) using ΔΔCt values.  Due to the 
inherently low transcription level in resting B cells, traditional methods of mRNA 
isolation/cDNA generation failed to yield reproducible results when ASCT2 expression 
levels were analyzed by qPCR.  Therefore, I optimized an “on column” method 
(Miltenyi Biotec) in which whole cell lysate is applied over a column to isolated mRNA,  
and the column is then heated to cycle through the RT-PCR reaction without the need for 
tube transfer (detailed protocol available through miltenyibiotec.com).  This system 
serves to minimize sample loss and ensure reproducible quantities of cDNA are 
generated from even low initial concentrations of mRNA.   While quiescent B cells 
express low levels of ASCT2, expression was found to increase in a time-dependent 
manner following B cell stimulation, with increased expression as early as 6 hours post 
BCR crosslinking and peak expression occurring after 18-24 hours (Figure14).  To 
confirm expression at the protein level, I developed a flow cytometry-based protocol. 
ASCT2 is a multispanning membrane protein that is highly susceptible to degradation 
following cell lysis.  This feature of the protein makes it very difficult to perform 
quantitative analysis of protein by SDS-PAGE and western blot.  There are no 
commercially available antibodies available that recognize extracellular epitopes of 
ASCT2, thus making it impossible to analyze surface expression in live cells by flow 
cytometry.  Analysis of membrane proteins with antibodies to intracellular epitopes 
presents additional difficulties, as disruption of the cell membrane to allow passage of 
the primary antibody can also alter the conformation of the protein or its embedment in 
the membrane, rendering it unrecognizable to the primary antibody.  To analyze 
expression of ASCT2 at the protein level, B cells were activated in culture for 0, 12, and 
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24 hours and then fixed with para-formaldehyde followed by gentle overnight 
permeabilization in 0.1% saponin buffer.  This method enabled me to accurately analyze 
ASCT2 expression at the protein level using flow cytometry.  Time-dependent 
upregulation of ASCT2 up to 24 hours was also observed at the protein level (Figure 
15).  These results establish that ASCT2 expression is induced during the first 24 hours 
after BCR ligation.   
 
Specific inhibition of ASCT2 mediated transport by the L-glutamine analog GPNA 
inhibits activation in a manner similar to that observed under L-glutamine depletion 
Having confirmed that ASCT2 is upregulated following B cell activation, I set 
out to determine whether inhibition of ASCT2 would induce aberrant activation similar 
to those observed in L-glutamine depleted conditions.  A glutamine analog, L-γ-
glutamyl-p-nitroanilide (GPNA) has been shown to act as a specific inhibitor of ASCT2 
mediated transport at millimolar concentrations.223  Small dense B cells were activated 
with anti-Ig in the presence or absence of 5 mM GPNA for 24 hours and analyzed for 
several activation parameters previously determined to be affected or not affected by a 
lack of extracellular glutamine.  Surface CD86 expression, which had been observed to 
increase in activated B cells regardless of glutamine availability, was not measurably 
affected by GPNA treatment (Figure 16).   I observed low surface CD71 expression at 
levels similar to that of naïve B cells in cells treated with GPNA, just as had previously 
been observed in glutamine deprived cells (Figure 17).  Total intracellular protein 
content increase was also diminished in anti-Ig stimulated B cells treated with GPNA 
(Figure 18).   Finally, GPNA treated B cells exhibited impaired cell size increase similar 
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to that observed in glutamine deprived cells as measured by Forward Scatter (Figure 
19a) and cell diameter (Figure 19b).  Collectively, these results suggest that ASCT2 
inhibition by GPNA is sufficient to produce activation defects parallel to those observed 
due to lack of extracellular glutamine, indicating that ASCT2 is a critical mediator of 
glutamine uptake following B cell receptor ligation. 
 
Extracellular L-leucine supplementation does not restore activation events in L-
glutamine depleted B cells 
Studies in cancer cell lines and T cells have uncovered a mechanism by which 
ASCT2 and LAT1 act in partnership to coordinate glutamine uptake and leucine 
uptake.162,164,165  In these studies, supplementation of the cell culture media with varying 
concentrations of leucine was able to reverse defects in autophagy and differentiation 
events in both GPNA treated cells or ASCT2 / LAT1 knockdowns or knockout 
mice.162,164   It is possible that the importance of ASCT2 activity during B cell activation 
is wholly or partly due to partnership with LAT1 for leucine uptake.  To determine 
whether this mechanism regulates B cell activation, B cells were treated with 5 mM 
GPNA or alternatively  cultured in glutamine depleted media and supplemented with 4 
mM or 7 mM extracellular leucine.  Cells were then analyzed for several activation 
parameters, including surface CD71 expression and cell size increase, and compared to 
cells activated in complete media.  Interestingly, although a marginal increase in cell size 
and CD71 expression was observed when GPNA treated cells were supplemented with 
extracellular leucine, no measurable rescue effect was observed when cells cultured in 
the absence of glutamine were supplemented with high extracellular leucine (Figure 20).  
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Similar results were obtained when cell size was examined by mean forward scatter; 
extracellular leucine did not rescue activation induced cell size increase during either 
GPNA treatment or glutamine depletion (Figure 21). 
 
Supplementation with a cell permeable form of α-ketoglutarate is able to rescue 
activation events in cells cultured without L-glutamine 
 Having determined that leucine supplementation failed to measurably restore 
activation effects in the absence of extracellular glutamine, it was evident that glutamine 
was providing a role other than to increase leucine import.   As described, glutamine has 
been established as an important metabolic substrate in several proliferating cell types, 
and is capable of feeding into several metabolic pathways.  The first two steps of 
glutamine metabolism serve to generate α-KG, and it is from here that glutamine-
derived carbon is able to enter the TCA cycle.  I therefore hypothesized that the 
production of α-KG from glutamine could be an essential function of glutamine during 
B cell activation, to allow glutamine to be used for ATP production or biosynthetic 
reactions.  To investigate the significance of glutamine-derived α-KG on B cell 
activation processes, a cell permeable α-KG analog was used, di-methyl 2-oxoglutarate 
(for the purposes of this work referred to as simply α-KG).173,224,225  Naïve B cells were 
cultured in complete media, media lacking glutamine supplemented with 6.9 mM di-
methyl-α-KG, or complete media containing 6-diazo-5oxo-L-norleucine (DON), an 
inhibitor of glutaminases.226,227  Initially, supplementation with the cell permeable α-KG 
analog was highly cytotoxic, most likely due to the associated pH decrease in the media 
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following its addition (pH ~6.95).  To combat this effect, cell culture media was 
readjusted to physiological pH 7.4 following the addition of α-KG, and filter sterilized.  
Supplementation of α-KG restored both cell size increase (Figure 22) and CD71 
expression (Figure 23) in the absence of extracellular glutamine, while DON treatment 
inhibited these events. 
 
mTORC1 activation depends on glutamine transport through ASCT2, as well as 
subsequent glutaminolysis 
Previous studies have shown that α-KG is required for mTORC1 activation by a 
mechanism that involves RAG GTPase recruitment to the lysosome.204 Interestingly, this 
pathway is necessary for T cell differentiation into effector subsets.136,190,195,196  Since 
mTORC1 is a mediator of cell growth and many of the activation defects observed in B 
cells in the absence of glutamine are growth related, we examined whether glutamine 
derived α-KG is required for mTORC1 activity.  For these studies, we monitored 
phosphorylation of S6, a downstream target of mTORC1, to measure mTORC1 activity.  
S6 is an ideal target to assay mTORC1 activity as it will only be phosphorylated 
downstream of mTORC1, and allows strict confirmation that mTORC1 has been 
activated.192  S6-pS235/236 was analyzed by flow cytometry and western blot in B cells 
under several different culture conditions shown (Figure 24a, 24b).  S6 phosphorylation 
increased in B cells activated for 24 hours with anti-Ig as compared to naïve B cells, 
which had very low levels of positive staining.  Glucose depletion had no effect on 
mTORC1 activity, however glutamine depletion markedly decreased levels of mTORC1 
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activity.  In contrast to recent work in T lymphocytes showing that supplementation with 
high extracellular levels of leucine rescued mTORC1 activity in an ASCT2 knockout 
mouse model, we found that leucine supplementation had no such rescuing effect in the 
absence of extracellular glutamine.162  Supplementation with extracellular α-KG was 
able to restore mTORC1 activity levels.  Additionally, treatment with GPNA or DON 
inhibited mTORC1 activity to an extent similar to that observed in the absence of 
glutamine.  These findings indicate that glutaminolysis derived α-KG is crucial for 
mTORC1 activity.  5’ AMP-activated protein kinase (AMPK) is an upstream regulator 
of mTORC1 that inactivates mTORC1 in response to decreased cellular ATP 
levels.129,155  AMPK classically becomes activated when glucose levels are low, and 
inhibits mTORC1 to decrease energy consuming reactions until ATP levels have been 
restored.153,154  Because AMPK is regulated by nutrient availability, I investigated 
whether it was activated in B cells in response to glucose or glutamine depletion.  Due to 
very high background staining when analyzing the phosphorylated, active form of 
AMPK by western blot, it is not possible to definitely state whether nutrient limitation 
has an activating effect.  However, p-AMPK levels do not appear to be significantly 
increased in glucose depleted cells (Figure 25), correlating with my finding that glucose 
depletion does not inhibit mTORC1 activity. 
 
α-ketoglutarate is not required for histone or DNA demethylation during B cell 
activation 
In addition to serving as a metabolic substrate in the TCA cycle, α-KG serves as a 
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required substrate for epigenetic remodeling enzymes TET and JHDM, responsible for 
DNA and histone demethylation respectively.179-181  To determine whether glutamine 
derived α-KG contributes epigenetic remodeling during B cell activation, the cell 
permeable α-KG analog was used.  Additionally, D-α-hydroxyglutaric acid (2HG), an 
analog of α-KG that cannot be utilized as a substrate by TET or JHDM was used as a 
negative control.184,185  To determine the effect of α-KG on DNA demethylation during 
B cell activation, global levels of 5-methylcytosine (5mC) were analyzed by flow 
cytometry (Figure 26).  No significant difference was observed between 5mC levels in 
quiescent cells and cells activated for 24 hours either in complete media, 2HG treated, or 
glutamine deprived and α-KG supplemented.  Although decreased 5mC levels were 
observed in glutamine deprived activated cells, this is possibly an effect of increased 
sub-G1 DNA content, since no other α-KG dependent changes in 5mC were observed.  
To examine whether α-KG is essential for histone demethylation, we examined levels of 
Histone 3 lysine 9 (H3K9) tri-methylation by western blot as compared to total Histone 
3 (H3) levels (Figure 27).  In fact, H3K9 Me3 was found to increase after 24 hours of 
anti-Ig stimulation, and this increase was independent of glutamine or α-KG availability.  
Although site-specific demethylation cannot be ruled out, this data indicates that 
glutamine derived α-KG is not required for global epigenetic remodeling by TET or 
JHDM enzymes. 
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FIGURES AND LEGENDS 
Figure 12. Glutamine uptake in activated B cells is primarily sodium-dependent.  B 
cells were stimulated with 300ng/mL PMA plus 400ng/mL ionomycin for 18 hours, then 
washed and resuspended in choline-KR buffer for 30 min. Transport was initiated by 
mixing cells with 200uL of choline-KR buffer with 4uCi/mL [3H] glutamine in the 
presence or absence of sodium. Cells were separated by centrifugation through a 
bromodecane and 20% perchloric acid gradient.  The perchloric acid layer was 
quantified using liquid scintillation spectrophotometry. Data is expressed as CPM/106 
cells/sec, sodium dependent uptake is shown in black and sodium independent uptake is 
shown in grey.  Each time point represents 3 independent uptake measurements.  
Experiment performed by CA Doughty, unpublished data. 
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Figure 12.  
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Figure 13. System ASC activity mediates glutamine uptake in B cells. Glutamine 
transport assay was performed as in (Figure 12) using [3H] glutamine alone, [3H] 
glutamine plus 1mM leucine (Leu), or [3H]  glutamine plus 1 mM threonine (Thr), in the 
presence or absence of sodium, with or without 1 mM methylaminoisobutryic acid 
(meth-AIB).  After 90 seconds, both sodium dependent and sodium independent uptake 
were performed in quadruplicate; the graph shows average sodium dependent uptake 
with average sodium independent uptake values subtracted, expressed as CPM/106 
cells/90 sec.   Experiment performed by CA Doughty, unpublished data. 
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Figure 13.  
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Figure 14. ASCT2 mRNA is upregulated in response to BCR cross-linking.  Naïve B 
cells were cultured complete media and stimulated with 10 µg/mL anti-Ig, and harvested 
at the indicated time points.  cDNA was prepared using MACS One-step cDNA 
Isolation Kit, and analyzed by qPCR for ASCT2 expression.  Expression was normalized 
using β2M as a control as described in the Materials and Methods.  Data is expressed as 
relative expression, and results are representative of 3 independent experiments.  Error 
bars represent standard deviation from the mean of relative expression.  
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Figure 14.  
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Figure 15.  ASCT2 protein is upregulated during B cell activation.  Naïve B cells 
were cultured in complete media and stimulated with 10 µg/mL anti-Ig for the indicated 
times, and compared to naïve cells.  Cells were collected and stained for ASCT2 
expression after fixation and permeabilization as described in the Materials and 
Methods.  Cells were analyzed by flow cytometry; results are representative of 3 
independent experiments; error bars represent standard deviation from the mean.  Data is 
expressed as Mean Fluorescence Intensity (MFI). 
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Figure 15.  
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Figure 16. Inhibition of ASCT2 mediated transport by GPNA does not impair 
CD86 upregulation.  Naïve B cells were activated with 10 µg/mL anti-Ig and cultured 
in either complete (nutrient replete) media or complete media containing 5mM L-γ-
glutamyl-p-nitroanilide (GPNA) for 24 hours and compared to naïve cells.  Cells were 
collected and then analyzed by flow cytometry for surface expression of CD86.  Data 
represents analysis of live gated B cells and is expressed as the percentage of cells 
positively stained for expression of CD86.  The data are representative of 3 independent 
experiments.  Error bars represent standard deviation from the mean.  Shown below are 
representative histograms of CD86 expression for cells cultured in complete media (red) 
or complete media plus 5 mM GPNA (green), overlaid with expression on naïve cells 
(grey). 
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Figure 16. 
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Figure 17. Inhibition of ASCT2 mediated transport by GPNA impairs CD71 
upregulation.  Naïve B cells were activated with 10 µg/mL anti-Ig and cultured in either 
complete (nutrient replete) media or complete media containing 5mM L-γ-glutamyl-p-
nitroanilide (GPNA) for 24 hours and compared to naïve cells.  Cells were collected and 
then analyzed by flow cytometry for surface expression of CD71.  Data represents 
analysis of live gated B cells and is expressed as Mean Fluorescence Intensity (MFI).  
The data are representative of 3 independent experiments.  Error bars represent standard 
deviation from the mean.  Shown below are representative histograms of CD71 
expression for cells cultured in complete media (red) or complete media plus 5 mM 
GPNA (green), overlaid with expression on naïve cells (grey). 
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Figure 17.  
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Figure 18. Inhibition of ASCT2 mediated transport by GPNA impairs increased 
intracellular protein content. Naïve B cells were activated with 10 µg/mL anti-Ig and 
cultured in either complete (nutrient replete) media or complete media containing 5mM 
L-γ-glutamyl-p-nitroanilide (GPNA) for 24 hours and compared to naïve cells.  Cells 
were collected and stained with FITC as described in the Materials and Methods, and 
analyzed by flow cytometry.  Data is expressed as Mean Fluorescence Intensity (MFI).  
Results are representative of 3 independent experiments.  Error bars represent standard 
deviation from the mean. 
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Figure 18.  
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Figure 19. Inhibition of ASCT2 mediated transport by GPNA impairs cell size 
increase following activation.  B cells were activated with 10 µg/mL anti-Ig and 
cultured in either complete media or complete media containing 5mM L-γ-glutamyl-p-
nitroanilide (GPNA) for 24 hours and compared to naïve cells.  A.  Cells were analyzed 
by flow cytometry for forward scatter, an indicator of cell size, gated on live cells.  Data 
is expressed as Mean Forward Scatter.  Results are representative of 3 independent 
experiments..  Error bars represent standard deviation from the mean.  B.  Cells were 
analyzed after 24 hours for mean cell diameter by the Millipore ScepterTM.  Data is 
expressed as mean cell diameter (microns).  Naïve cells are shown in blue, complete 
media shown in red, GPNA treated shown in green.  Results are representative of 3 
independent experiments.   
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Figure 19. 
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Figure 20. Extracellular L-leucine supplementation does not rescue CD71 
expression in the absence of L-glutamine.  Naïve B cells were activated with 10 
µg/mL anti-Ig and cultured in either complete media, media lacking L-glutamine, media 
lacking L-glutamine supplemented with 4mM or 10mM L-leucine, complete media 
containing 5mM GPNA, or complete media containing 5mM GPNA supplemented with 
4mM or 10mM L-leucine for 24 hours.   Cells were analyzed by flow cytometry for 
surface expression of CD71, gated on live cells.  Data is expressed as Mean 
Fluorescence Intensity.  Results are representative of 3 independent experiments.  Error 
bars represent standard deviation from the mean.  Representative histograms of CD71 
expression are shown below; legend indicates lines used to represent culture conditions. 
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Figure 21. Extracellular L-leucine supplementation does not rescue cell size.  B cells 
were activated with 10 µg/mL anti-Ig and cultured in either complete media, media 
lacking L-glutamine, media lacking L-glutamine supplemented with 4mM or 10mM L-
leucine, complete media containing 5mM GPNA, or complete media containing 5mM 
GPNA supplemented with 4mM or 10mM L-leucine for 24 hours. Cells were analyzed 
by flow cytometry for forward scatter, an indicator of cell size, gated on live cells.  Data 
is expressed as Mean Forward Scatter (Mean FSC).  Results are representative of 3 
independent experiments.  Error bars represent standard deviation from the mean.  
Representative histograms of CD71 expression are shown below; legend indicates lines 
used to represent culture conditions. 
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Figure 22. Glutaminolysis contributes to increased cell size.  Naïve B cells were 
activated with 10 µg/mL anti-Ig and cultured in either complete media, media lacking L-
glutamine supplemented with 6.9mM α-KG, or complete media containing 40µM DON 
for 48 hours and compared to naïve cells.   Cells were analyzed by flow cytometry for 
forward scatter, gated on live cells.  Data is expressed as Median Forward Scatter 
(Median FSC), results are representative of two independent experiments.  Error bars 
represent standard deviation from the mean. 
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Figure 22. 
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Figure 23. Glutaminolysis contributes to increased CD71 expression.  Naïve B cells 
were activated with 10 µg/mL anti-Ig and cultured in either complete media, media 
lacking L-glutamine supplemented with 6.9mM α-KG, or complete media containing 
40µM DON for 48 hours and compared to naïve cells.  Cells were analyzed by flow 
cytometry for surface expression of CD71, gated on live cells.  Data is expressed as 
Mean Fluorescence Intensity.  Results are representative of 3 independent experiments.  
Error bars represent standard deviation from the mean. 
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Figure 23. 
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Figure 24. Glutaminolysis is essential for mTORC1 activity.  Naïve B cells were 
activated with 10 µg/mL anti-Ig and cultured in either complete media, media lacking 
glucose, media lacking L-glutamine, media lacking L-glutamine supplemented with 4 
mM L-leucine, media lacking L-glutamine supplemented with 6.9 mM α-KG, complete 
media containing 5 mM GPNA, complete media containing 40 µM 6-diazo-5-oxo-L-
norleucine (DON), or complete media containing 20 nM rapamycin for 24 hours and 
compared to naïve cells.   A. Cells were fixed and permeabilized as described in the 
Materials and Methods and analyzed by flow cytometry for intracellular expression of 
S6-pSer235/236 to determine activity of mTORC1.  Data is expressed as the mean 
percentage of cells that stained positively for p-S6 of 3 independent experiments, error 
bars represent standard deviation from the mean. A minimum of 5000 cells were counted 
in each sample/condition.  B.  Cellular lysates were prepared in Triton-X 100 buffer after 
24 hours in culture.  Equivalent amounts of total protein were analyzed for expression of 
S6-pSer235/236 or total S6 by western blot as described in the Materials and Methods. 
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Figure 24. 
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Figure 25.  AMPK phosphorylation is not clearly affected by glucose availability 
when analyzed by western blot.  Naïve B cells were activated with 10 µg/mL anti-Ig 
and cultured in either complete media, media lacking glucose, media lacking L-
glutamine, media lacking L-glutamine supplemented with 4 mM L-leucine, or media 
lacking L-glutamine supplemented with 6.9 mM α-KG for 24 hours and compared to 
naïve cells.   Cellular lysates were prepared in Triton-X 100 buffer after 24 hours in 
culture.  Equivalent amounts of total protein were analyzed for expression of S6-
pSer235/236 or total S6 by western blot as described in the Materials and Methods. 
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Figure 25. 
 
  
 
  
  
Naive Complet
e 0mM	Gluc
ose 
0mM	Gln 0mM	G
ln	+	a-KG 0mM	Gln	
+	Leu 
P-AMPK 
AMPK 
106		
Figure 26. FACS analysis of global DNA demethylation does not indicate a 
contribution of glutaminolysis.  B cells were activated with 10 µg/mL anti-Ig and 
cultured in either complete media, media lacking glucose, media lacking L-glutamine, 
media lacking L-glutamine supplemented with 4mM L-leucine, media lacking L-
glutamine supplemented with 6.9 mM α-KG, or complete media containing 5 mM 2HG 
for 24 hours and compared to naïve cells.   Live cells were sorted by PI exclusion and 
purified using BD FACSAria cell sorter.  Cells were then fixed, permeabilized, and 
DNase treated using the BD BrdU kit according to the manufacturers instructions.  Cells 
were stained using an anti-5-methylcytosine antibody and analyzed by flow cytometry.  
Data is expressed as Mean Fluorescence Intensity (MFI).  Results are representative of 2 
independent experiments.  Error bars represent standard deviation from the mean. 
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Figure 27. Global histone demethylation is not measurably affected by 
glutaminolysis during B cell activation.  Naïve B cells were activated with 10 µg/mL 
anti-Ig and cultured in either complete media, media lacking glucose, media lacking L-
glutamine, media lacking L-glutamine supplemented with 4mM L-leucine, media 
lacking L-glutamine supplemented with 6.9mM α-KG, or complete media containing 
5mM 2HG for 24 hours and compared to naïve cells.   Cellular lysates were prepared in 
RIPA buffer after 24 hours in culture.  Equivalent amounts of total protein were 
analyzed for expression of tri-methyl H3K9 or total Histone 3 by western blot, as 
described in the Materials and Methods. Results are representative of 2 independent 
experiments.   
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Figure 27. 
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CHAPTER FIVE 
Nutrients regulate B cell functions and differentiation   
111		
RESULTS 
 
Glut1 upregulation occurs in a L-glutamine dependent manner following BCR 
crosslinking.  mTORC1 activity and glutaminolysis are partly necessary for activation 
induced Glut1 upregulation. 
Glut1 is the primary mediator of glucose transport in B lymphocytes, and while 
expressed at low levels in quiescent cells it is upregulated in response to B cell 
stimulation.131,132,134  In work previously published, the Chiles lab demonstrated that 
mTORC1 inhibition caused a moderate decrease in glucose uptake and glycolysis.  This 
work also established that inhibition of PI3K signaling had a more complete inhibitory 
effect on glucose uptake and metabolism in B cells.131  Although mTORC1 activity is 
only partly required for glucose metabolism, I sought to investigate whether glutamine 
availability could act through mTORC1 signaling to promote glucose transporter 
expression, as has been suggested by studies in other cell types.228,229  To determine the 
role of glutamine mediated mTORC1 activity in Glut1 upregulation, I analyzed Glut1 
expression by flow cytometry. As previously described, Glut1 was upregulated in B cells 
activated with anti-Ig in complete media as compared to naïve cells, and this 
upregulation occurred in a time dependent manner.  Interestingly, glucose depletion 
prompted a slight increase in Glut1 induction as compared to cells activated in complete 
media, while L-glutamine depletion abrogated this time-dependent upregulation (Figure 
28).  L-glutamine depletion also appeared to inhibit Glut1 expression at later time points, 
in line with our results indicating that very early activation events up to 12 hours 
following BCR crosslinking can proceed in the absence of L-glutamine.  To further 
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characterize the effects of L-glutamine limiting conditions, we analyzed Glut1 
expression after 24 hour anti-Ig stimulation in conjunction with inhibitors of L-
glutamine uptake (GPNA), or mTORC1 activity (rapamycin).  L-Glutamine depletion 
and GPNA treatment both inhibited Glut1 upregulation, with expression levels observed 
similar to that in naïve cells.  This finding indicates that L-glutamine uptake through the 
transporter ASCT2 is essential for maximal induction of Glut1 during B cell activation.  
Rapamycin treatment resulted in expression levels below that observed in naïve cells 
(Figure 29).  When taken together with our finding that L-glutamine availability is 
required for mTORC1 activity, this result indicates that glutamine availability acts 
through regulation of mTORC1 activity to affect Glut1 expression levels.   
 
mTORC activity and L-glutamine availability are required for increased glucose 
uptake following B cell activation 
To determine the functional significance of decreased Glut1 expression in 
activated B cells, I measured glucose uptake using a cell permeable fluorescent analog of 
glucose, 2NBDG.230,231  Glucose uptake was increased in anti-Ig stimulated B cells as 
compared to naïve cells, and was actually increased in glutamine starved and rapamycin 
treated cells, however not to the maximal extent observed in complete media (Figure 
30).  This implies there is a functional significance of decreased Glut1 expression in the 
absence of glutamine or mTORC1 activity that can be correlated to decreased glucose 
uptake.   
 
ATP citrate lyase (ACLY) activity is required to support endomembrane expansion 
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during B cell activation 
Additional work in the Chiles lab has focused on investigating the role of glucose 
metabolism in support of de novo lipid synthesis during B cell activation.  It is important 
to note that to examine B cell differentiation events that occur later than cell cycle entry, 
such as Ig production and CD138 expression, naïve B cells require LPS to induce 
differentiation into plasma Ig secreting cells.74,232 Stimulation with anti-Ig is only 
sufficient to induce early signaling events, cell growth, and S phase entry, however does 
not provide the necessary stimulus for differentiation events.  For this reason, LPS was 
utilized as the stimulant for experiments looking at endomembrane expansion and 
induction of plasma cell markers (e.g., CD138, Blimp1), as this method of stimulation is 
capable of inducing differentiation of naïve B cells within several days. Our previous 
work suggested that ACLY activity is required for glucose-dependent de novo synthesis 
of neutral and acidic lipids, including phosphatidylcholine (PC) and ceramide (CM); 
both of these lipids are required for endoplasmic reticulum (ER) expansion in B 
lymphocytes.133,233  It therefore seemed likely that ACLY activity might contribute to 
expansion of the endomembrane secretory network in response to LPS stimulation. To 
assess the expansion of the ER compartment, I stained ex vivo B lymphocytes with ER-
TrackerTM Green, an ER-specific probe. Intracellular staining of B cells cultured in the 
absence of LPS revealed a small area of staining that expanded substantially following 
stimulation with LPS for 24 h and 48 h (Figure 31b). Treatment of LPS-stimulated B 
cells with C-9 or Medica 16, two specific ACLY inhibitors with distinct mechanisms of 
action, resulted in decreased and/or altered intracellular staining.  Flow cytometry of ER-
TrackerTM stained B cells also revealed a significant reduction in mean fluorescence 
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intensity in LPS-stimulated B cells treated with C-9 (Figure 31a).  For these 
experiments, the viable B cell population was gated and subsequently analyzed for 
fluorescence intensity by flow cytometry. 
 
ACLY activity is required for LPS induced plasma-like phenotypic changes  
To investigate further the involvement of ACLY activity in plasma-like B cell 
differentiation, I evaluated whether ACLY activity was required for LPS-induced 
surface CD138 (Syndecan-1) expression in splenic B lymphocytes; CD138 is expressed 
upon B cell differentiation into plasmablasts and plasma cells.234,235 LPS stimulation of 
splenic B cells increased surface CD138 expression (Figure 32). To minimize the 
confounding effects of decreased viability at later time points observed with C-9, B cells 
were instead treated with Medica 16, a small molecule inhibitor of ACLY that is 
structurally unrelated to C-9 and has been used both in vitro and in vivo. Treatment of 
LPS-stimulated B cells with Medica 16 resulted in a significant reduction in CD138 
expression in viable B cells analyzed by flow cytometry (Figure 32). I also evaluated the 
expression of Blimp-1, which is required for development of immunoglobulin-secreting 
cells and for maintenance of long lived plasma cells.236 I found that LPS-induced Blimp-
1 expression was reduced in splenic B cell cultures incubated with Medica 16 (Figure 
33). 
 
Nutrients are not required for antigen-receptor endocytosis and trafficking 
In order to further determine functional relevance of nutrient availability, I 
sought to investigate the effects of glucose or glutamine limiting conditions on antigen 
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presentation by B cells.  In order to present antigen on MHCII, B cells must first 
endocytose bound BCR-antigen complex and transport it to the lysosome, where antigen 
will undergo processing and MHCII loading to be transported back to the cell 
surface.76,237,238  The lysosome is also the site of mTORC activation, and I hypothesized 
that perhaps lysosomal localization is negatively impacted in the absence of glutamine or 
glucose.204  An established technique for examining antigen-receptor endocytosis and 
transport to the lysosome by microscopy has been described in the literature.237  Using 
this technique and in collaboration with Mary Ann Collins in the Folker laboratory, I 
examined colocalization of BCR and the lysosomal associated membrane protein 
(LAMP-1) at 0, 15, and 60 minutes following BCR crosslinking.  BCR endocytosis and 
lysosomal targeting occur rapidly following BCR crosslinking, and colocalization can 
typically be observed within 30-60 minutes.237  My findings indicate that BCR 
endocytosis and trafficking occurs independently of either glucose or glutamine 
availability (Figure 34).   
 
Glutamine uptake contributes to LPS induced differentiation in IL-10 secreting 
regulatory B cells  
Several recent studies have demonstrated that in T cells, limited glutamine 
availability or ASCT2 knockout led to increased differentiation into regulatory T cell 
subsets, with concurrent decreased differentiation into pro-inflammatory 
subsets.162,191,196  To investigate whether glutamine availability similarly regulated 
differentiation into B cells, I chose to focus on differentiation into the IL-10 secreting 
regulatory B cell subset, so called B10 cells.108,110  These cells have been shown to play 
116		
important roles in autoimmune disease states, and are negative regulators of T cell pro-
inflammatory responses.115,116  B10 cell differentiation from naïve splenic B cells can be 
induced in culture by LPS stimulation, followed by PMA and ionomycin treatment.  LPS 
stimulation times of up to 48 hours, followed by 5 hours of PMA and ionomycin 
treatment have been shown to maximally increase B10 differentiation, with about 8% of 
cells exhibiting an IL-10 secretion phenotype.207  To study the role of glutamine in 
regulating B10 differentiation, naïve splenic B cells were stimulated with LPS and 
cultured in complete media, or media lacking glutamine for 48 hours.  During the final 5 
hours of culture, cells were treated with the addition of PMA and ionomycin to induce 
differentiation, and monensin to inhibit protein transport and retain any secreted IL-10, 
for intracellular staining, as described in the literature.207 LPS stimulation in the absence 
of extracellular glutamine resulted in a near complete block in intracellular IL-10 
accumulation as determined by flow cytometry (Figure 35).  Additionally, IL-10 
secretion was investigated by ELISA to quantitate concentrations of IL-10 in cell culture 
supernatants of B cells stimulated with LPS for 72 hours (Figure 36).  Glutamine 
depletion resulted in decreased IL-10 secretion, as did GPNA treatment, as compared to 
cells stimulated in complete media.  These results indicate that ASCT2 mediated 
glutamine uptake contributes to LPS induced B10 differentiation in vitro.  
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FIGURES AND LEGENDS 
Figure 28. Upregulation of Glut1 occurs in a time dependent manner and depends 
on extracellular L-glutamine availability.  Naïve B cells were activated with 10 
µg/mL anti-Ig and cultured in either complete media (Dark Blue), media lacking glucose 
(Green), or media lacking L-glutamine (Light Blue) for 6, 12, or 24 hours and compared 
to naïve cells (white).   Cells were collected then fixed and permeabilized and analyzed 
by flow cytometry for expression of Glut1 as described in the Materials and Methods.  
Data is expressed as Mean Fluorescence Intensity (MFI).  Results are representative of 2 
independent experiments.  Error bars represent standard deviation from the mean. 
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Figure 28.  
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Figure 29. Upregulation of Glut1 depends on glutamine uptake and mTORC 
activity.  Naïve B cells were activated with 10 µg/mL anti-Ig and cultured in either 
complete media, media lacking glucose, media lacking L-glutamine, complete media 
containing 5mM GPNA, or complete media containing 20 nM rapamycin for 24 hours 
and compared to naïve cells.   Cells were fixed and permeabilized and analyzed by flow 
cytometry for expression of Glut1 as described in the Materials and Methods.  Data is 
expressed as Mean Fluorescence Intensity (MFI).  Results are representative of 2 
independent experiments.  Error bars represent standard deviation from the mean. 
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Figure 29. 
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Figure 30. Glut1 expression levels correlate with glucose uptake.  Naïve B cells were 
activated with 10 µg/mL anti-Ig and cultured in either complete media, media lacking L-
glutamine, or complete media containing 20nM rapamycin for 24 hours and compared to 
naïve cells. Cells were harvested after 24 hours in culture, washed, and incubated in 
media lacking glucose for 4 hours.  Cells were then incubated in culture medium 
containing 150 µg/mL 2-NBDG for 30 minutes and analyzed by flow cytometry, gated 
on live cells.  Data is expressed as Mean Fluorescence Intensity (MFI).  Results are 
representative of 3 independent experiments.  Error bars represent standard deviation 
from the mean. 
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Figure 30.  
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Figure 31. ACLY activity is required for increased endoplasmic reticulum 
membrane expansion in LPS-stimulated B lymphocytes.  A. B cells were cultured in 
medium alone (Media) or stimulated with 50 µg/ml LPS. Parallel LPS-stimulated B cells 
were treated with 50 µM compound-9 (LPS + C9) for 48 h. Cells were collected, and ER 
content was assessed by staining with ER-TrackerTM and flow cytometry. The data are 
expressed as mean fluorescence intensity (MFI). Error bars, S.D. of two independent 
measurements. B. B cells were cultured in medium alone or stimulated with 50 µg/ml 
LPS. Parallel LPS-stimulated B cells were treated with 50 µM compound-9 (C9) or 40 
µM Medica 16 for the indicated times. Cells were then collected and stained with ER-
TrackerTM in order to assess ER content and fluorescence microscopy as described under 
“Experimental Procedures.”  
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Figure 32. ACLY activity is required for LPS-induced CD138 upregulation in B 
lymphocytes. B cells were cultured in medium alone or stimulated with 50 µg/ml LPS 
for 72 h; parallel LPS-stimulated B cells were treated with 40 µM Medica 16 
(LPS+Medica 16). Cells were then evaluated for the expression of surface CD138 
expression by flow cytometry following gating on the viable cell population.  The data 
are expressed as mean fluorescence intensity (MFI). Error bars, S.D. of two independent 
measurements. 
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Figure 32.  
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Figure 33. ACLY activity is required for LPS-induced Blimp-1 induction in B 
lymphocytes. B cells were cultured in medium alone or stimulated with 50 µg/ml LPS 
for 72 h; parallel LPS-stimulated B cells were treated with 40 µM Medica 16 
(LPS+Medica 16). Cells were evaluated for the expression of Blimp-1 by flow cytometry 
following gating on the live cell population.  The data are represented as percentage of 
Blimp-1+ B cells. Error bars, S.D. of two independent measurements. 
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Figure 33. 
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Figure 34. Nutrients are not required for early antigen-receptor endocytosis and 
trafficking.  Cellular localization of BCR (green) and LAMP-1 (red) in purified, naïve B 
cells 0-60 minutes following BCR crosslinking in either complete media (Comp), media 
lacking glutamine, or media lacking glucose.  106 Naïve B cells were stained and 
analyzed by confocal microscopy as described in the Materials and Methods.  
Experiments were performed in duplicate; images are representative of the overall cell 
population. 
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Figure 34. 
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Figure 35. ASCT2 mediated glutamine uptake is required for LPS induced B10 
differentiation. Naïve B cells were cultured in complete media or media lacking 
glutamine and stimulated with 10 µg/ml LPS for 48 hours, treated with 100 nM PMA, 
500 nM ionomycin, and 2 µM monensin for the final 5 hours.  Cells were fixed and 
permeabilized and evaluated for cytoplasmic IL-10 by flow cytometry as described in 
the Materials and Methods.  Data is shown as a representative plot of cell size vs. IL-10 
fluorescence, gated on the percentage of IL-10 positive cells.  Results are representative 
of 3 independent experiments. 
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Figure 35. 
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Figure 36. ASCT2 mediated glutamine uptake is required for LPS induced IL-10  
secretion. Naïve B cells were cultured in complete media, media lacking glutamine, or 
complete media containing 5 mM GPNA and stimulated with 10 µg/ml LPS for 72 hours 
and compared to naïve cells.  Cell culture supernatants were collected and IL-10 
concentrations were determined by ELISA.  Data is presented as the average IL-10 
concentration of three replicates, error bars display standard deviation from the mean. 
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Figure 36. 
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CHAPTER SIX 
Discussion 
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The regulation of nutrient uptake and metabolism to support growth and 
proliferation during B cell activation remains a poorly understood area of research.  
Early studies have established several decades past that mixed lymphocyte populations, 
following antigen recognition, engage in increased glucose and glutamine consumption 
and upregulate metabolic enzymes to process these nutrients.42,149,211  This increased 
nutrient consumption supports cellular growth and proliferation, as well as provides 
energy in the form of ATP to fuel cellular processes.  Although in recent years, much 
work has been accomplished to address these questions specifically in T cells, 
comparatively few studies have been conducted to address nutrient utilization during the 
B cell response.  Considering the substantial functional differences between the T cell 
mediated immune response and the B cell mediated humoral immune response, it is 
reasonable to conceive that the regulation of B cell metabolism during the activation 
response may significantly differ from that of T cells.  In support of this theory, work 
has shown that following receptor crosslinking, T cells increase glycolysis to a greater 
extant from the resting state than B cells with a comparative decrease in oxidative 
phosphorylation (OXPHOS), while B cells utilize glycolysis and OXPHOS to similar 
extents.134  Since so little is known about how B cells utilize nutrients to fuel growth and 
proliferation, one of the aims of this study was to shed new light on this process. 
My research suggests that both extracellular L-glutamine and glucose are 
dispensable for very early activation events following BCR crosslinking, as 
demonstrated by unperturbed expression of CD86.  However, later growth related events 
including CD71 upregulation, cell size increase, and protein and DNA synthesis are 
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strictly dependent on the availability of extracellular L-glutamine.  In contrast, 
extracellular glucose is only partially required for these later activation events to occur, 
with glucose depleted B cells displaying slightly inhibited growth related responses.  To 
fuel these growth related events, glutamine uptake increases rapidly following BCR 
crosslinking and in a sodium-dependent and system ASC dependent manner.  The high 
affinity L-glutamine importer, ASCT2, is upregulated following B cell activation.  
Inhibition of ASCT2 mediated transport by GPNA treatment caused similar activation 
defects to those observed during L-glutamine starvation, highlighting the essential nature 
of ASCT2 mediated glutamine import.  Interestingly, in contrast to studies in T-cells, L-
leucine supplementation provided limited to no rescuing effect on these defects, 
indicating that L-glutamine or its metabolic products are essential.162  Indeed, we found 
that supplementation with a cell permeable form of α-KG was able to restore activation 
events, including mTORC1 activity.  Inhibition of the glutaminolytic enzyme 
glutaminase by DON also resulted in decreased mTORC1 activity and limited cell 
growth events, as did inhibition of ASCT2 mediated L-glutamine uptake by GPNA.  
mTORC1 activity is known to increase Glut1 expression at the cell surface and on this 
point,  we observed that under conditions of L-glutamine depletion, GPNA treatment, or 
rapamycin treatment resulted in failure to increase BCR-induced Glut1 expression levels 
and glucose uptake comparably to high glutamine conditions. These findings reveal a 
possible nutrient sensing mechanism during B cell activation, by which mTORC1 
activity senses extracellular glutamine availability via α-KG, and a lack of extracellular 
glutamine results in failure to undergo the growth events normally associated with B cell 
activation, including cell size increase, protein content, and nutrient 
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receptors/transporters.  This also provides interesting insight to the fact that the 
glutamine requirement precedes the glucose requirement during B cell activation, in that 
initial glutamine availability actually regulates the increase in glucose uptake.  Together 
these results demonstrate a mechanism coupling the utilization of these two distinct 
nutrients through mTORC1 that has not previously been observed in B cells (Figure 1). 
 
Figure 1.  Model of mTORC1 coordination of nutrient uptake and metabolism.  
Glutamine imported through ASCT2 is metabolized to α-KG, which positively regulates 
mTORC1.  In turn, mTORC1 contributes to Glut1 induction and glucose uptake. 
 
Distinct glucose and glutamine requirements during early B cell activation 
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nutrient molecules that are not interchangeable during early B cell activation.  Glucose 
and glutamine are capable of being utilized in many of the same metabolic pathways, 
most notably by feeding into the TCA cycle to generate ATP or used as a carbon source 
for biosynthesis of macromolecules including lipids, proteins, and nucleic acids.  
However, their metabolism differs in several important ways, for instance, prior to 
entering the TCA cycle, glucose must undergo glycolysis.  This process provides 
opportunity for glucose to be diverted from the TCA cycle such via the production of 
lactate from pyruvate, or through the pentose phosphate pathway.148,149,211  These 
alternate pathways of glucose utilization allow glucose derived carbon to fuel the 
biosynthesis of macromolecules that contribute to cell growth and division including 
lipids and nucleotides. Contrastingly, glutamine may only undergo two catalyzed 
reactions, the first steps in all metabolic reactions of glutamine, to produce α-KG.158   
This includes the enzyme catalyzed conversion of glutamine to glutamate, followed by 
conversion of glutamate to α-KG as catalyzed by GLS.  α-KG can then directly enter the 
TCA cycle, in a much shorter pathway than glucose-derived acetyl-coA.  Additionally, 
glutamine has no alternative ATP generating pathway such as glycolysis, making TCA 
cycle entry essential to the production of ATP via glutamine metabolism.158  Glutamine 
can additionally contribute to the biosynthesis of amino acids, as well as act as an 
obligate nitrogen donor during nucleotide biosynthesis.149  These are just a few of the 
distinctions between glutamine and glucose metabolism, underlining the potential for 
alternative roles of these two nutrients in cellular metabolism. 
Stable isotope tracer labeling experiments, in which cells were cultured with 
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either 13C labeled glucose or glutamine indicate that LPS-stimulated B cells 
preferentially utilize glucose-derived carbon during the initial stages of activation 
response including the proliferative phase, but switch to a metabolic program that 
preferentially utilizes glutamine-derived carbon to support Ig production.135  This study 
represents one of the few examples of work to investigate the differential requirement 
for glucose and glutamine during B lymphocyte differentiation.  Although my studies 
found that the glutamine requirement preceded the glucose requirement, contrasting with 
the proposed order of nutrient utilization in the B cell stable isotope experiments, it is 
important to note that the stimulating agent in the experiments presented herein was anti-
Ig and not LPS, which could account for the differences in our data .  LPS is recognized 
by TLRs as opposed to the BCR and signals through distinct pathways.74,82,232  
Additionally, the published tracer experiments were not carried out under limiting 
glucose or glutamine in cell culture media during activation and differentiation.  It is not 
known whether in the absence of one or both of these nutrients the regulation of B cell 
activation is altered.  It is also possible that early glutamine regulation of mTORC1 acts 
as a nutrient sensing mechanism.  This mechanism has been proposed for nutrient 
regulation of T cell responses.162,206  In our B cell model, mTORC1 regulation could 
inhibit the cell from entering G1 in the case of insufficient extracellular glutamine 
concentrations for later Ig synthesis.  Our finding that low concentrations of extracellular 
glutamine were sufficient to restore defects associated with glutamine depletion, while 
glucose depletion appeared to have a concentration dependent effect is interesting in this 
context.  If glucose is primarily metabolized during early stages of B cell activation, 
lower concentrations would lead to lower levels of required metabolites such as citrate 
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required for lipid synthesis or nucleotides produced via the pentose phosphate pathway.  
Low levels of glutamine, conversely, could be sufficient to signal through mTORC1 that 
extracellular glutamine was available and to allow the cell to proceed through the 
glucose-metabolizing stage. 
Amino acids and mTORC1 coordinate cellular metabolism in lymphocytes 
Recent work has provided insight into the role of amino acid uptake and 
increased glycolytic metabolism in the regulation of T cell responses and the ability of 
mTORC1 to direct metabolic rewiring that is essential to CD4+ T cell 
differentiation.191,205,206,225  CD4+ T cells stimulated under appropriate conditions have 
the capacity to differentiate into TH1, TH2, TH17, or Tregs.  Differentiation into TH 
subsets is mTOR-dependent, with mTORC1 signaling being critical for TH1 and TH17 
generation, while mTORC2 is required for TH2.187,189,190  Treg differentiation is impaired 
by mTORC activity due to the downregulation of FoxP3 by both mTORC1 and 
mTORC2.190,195  mTORC is believed to regulate these differentiation programs through 
metabolic reprograming (Figure 2).  mTORC1 promotes a glycolytic phenotype through 
increased glucose uptake and metabolism, and TH1 and TH17 subsets are known to be 
highly glycolytic while Tregs rely primarily on lipid oxidation for ATP 
generation.187,191,196,239  As discussed above, B cells are also capable of differentiation 
into different subsets of effector or regulatory cells following activation.106  Little is 
known about the regulatory mechanisms that control B effector differentiation, and it 
remains to be addressed whether reprogramming of cellular metabolism plays a role in 
directing differentiation. 
143		
 Importantly, inhibition of amino acid uptake by knocking out either ASCT2 or 
LAT1 in mice recapitulated the differentiation changes associated with mTORC1 
inhibition in CD4+ T cells, exposing the ability of mTORC1 to coordinate nutrient 
availability and differentiation.162,165  Germane to my studies, it was reported that 
ASCT2 knockout mice contained decreased numbers of mature B cells in the spleen, 
indicating that ASCT2 mediated amino acid import is essential during B cell 
development and/or peripheral maintenance.162  For instance, ASCT2-mediated 
glutamine uptake may be essential during a proliferative phase of B cell development 
(e.g., at the large Pre-B cell stage in the bone marrow).  Inhibition of proliferation during 
this stage of development could lead to lower total numbers of mature B cells. ASCT2 
could alternatively be required for maintenance of mature B cells in the periphery by 
promoting cell survival or decreasing apoptosis and/or for expansion of B cells in 
response to antigen recognition.  The results of my research  indicate that GPNA 
treatment inhibits B-cell growth and proliferation responses by limiting ASCT2 
mediated glutamine uptake and mTORC1 activity.  This provides evidence to support 
the possibility that ASCT2 is critical for cell cycle entry in response to antigen 
encounter, which likely contributes to the number of splenic B cells.  Interestingly, the 
timeline of maximum ASCT2 upregulation in B cells corresponds to the time at which 
negative effects of glutamine depletion are observed (24 hours).  Although it is likely 
that many nutrient transporters in addition to ASCT2 are upregulated during these initial 
24 hours as this is the time during which the B cell becomes highly transcriptionally and 
translationally active, it is important to note the correlation.186,240  It is possible that the 
time at which maximum glutamine import would normally occur is due to a requirement 
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for glutamine for growth and signaling events at that specific time, and in the absence of 
glutamine these events can not proceed. 
 
Figure 2. Cellular metabolism and level of mTORC activity regulate T effector 
differentiation, adapted from (240) (permission not required to reprint).  Following TCR 
stimulation, CD4+ T cells can differentiate into one of four effectors based on receipt of 
cytokine signals.  This differentiation is also regulated by mTORC1 activity and cellular 
metabolism, with high mTORC1 activity and glycolysis promoting differentiation into 
pro-inflammatory subtypes.239 
 
Notably, the ASCT2 knockout mouse study did not examine the effects of 
complete deprivation of glutamine from the cell culture media.162  Therefore, it is 
possible that low concentrations of glutamine were still being imported into the cell 
through other transporters, in a “leaky” rescue mechanism.  This correlates with my 
results in that extracellular leucine supplementation was able to partially rescue 
inhibition of ASCT2 by GPNA treatment, allowing that glutamine could be carried into 
the cell by other transporters.  However, the inability of leucine to rescue cell growth 
related events from complete deprivation of glutamine, along with inability to restore 
mTORC1 activity to any degree, indicates that glutamine is essential.  Of note, I did not 
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culture B cells in the absence of extracellular leucine and therefore I cannot rule out the 
possibility that leucine availability may be also essential for cell growth and mTORC1 
activity.  Within the scope of my study it can be concluded that glutamine is certainly 
necessary, whereas leucine alone is not sufficient for mTORC1 activity and growth 
related B cell activation responses. 
The interplay between mTOR activity and cellular metabolism has been further 
established in a recent study demonstrating that glucose depletion resulted in AMPK 
activation and inhibition of mTORC1 in CD4+ T cells.129  AMPK negatively regulates 
mTORC1 in response to low intracellular ATP levels in order to limit energy consuming 
growth reactions until ATP levels are restored. In this study described by the Jones 
laboratory, an alternative energy pathway relying on glutamine metabolism and 
oxidative phosphorylation instead of glycolysis was utilized to promote T cell 
survival.129  In my studies AMPK activity did not appear to be increased in the absence 
of glucose as determined by western blot, nor was mTORC1 activity diminished as 
shown by levels of S6 phosphorylation.  In fact, the percentage of B cells with positive 
P-S6 staining was increased in B cells activated in the absence of glucose. My 
investigation also demonstrates that mTORC1 activity contributes to Glut1 upregulation 
and glucose uptake in B cells.  Taken together, these results indicate that mTORC1 
activity is likely acting primarily upstream of glucose in anti-Ig activated B cells.  This 
represents a regulatory mechanism that is distinct from that observed in T cells.  
The role of mTOR in B cells has been studied extensively, and in several 
previous studies, B cells have been demonstrated to be generally more sensitive to the 
effects of mTORC1 inhibition than T cells.186,241  For example, the inhibition of TCR 
146		
stimulated proliferation in T cells by rapamycin is markedly less than that in BCR 
stimulated B cells, with rapamycin treatment causing a near complete block in 
proliferation of murine B cells stimulated with anti-Ig.241-243  The decreased proliferation 
was not correlated with decreased cell survival, indicating a mechanism distinct from 
autophagy or apoptosis, although the precise blocking mechanism remains unclear.242  
This correlates with our finding that in the absence of extracellular glutamine, activated 
B cells did not suffer decreased viability, providing further indication that glutamine is 
acting through an mTORC1-regulated mechanism. It is also known that different 
methods of in vitro activation of B cells (LPS vs. anti-Ig) have been shown to 
differentially regulate mTORC1 activity.244  Additionally, different subsets of mature, 
resting B cells have been shown to have differing basal levels of mTORC1 activity; FO 
B cells have low levels of basal mTORC1 activity, while MZ B cells have higher basal 
activity levels, and this basal activity is augmented by the addition of amino acids to cell 
culture media.244  mTORC1 and mTORC2 likely also have an important role in B cell 
development; an mTOR hypomorph mouse model had a partial block of development at 
the large pre-B to small pre-B stage, as well as decreased numbers of MZ and 
transitional B cells in the periphery.245  These key findings demonstrate the importance 
of mTORC signaling, and the regulation of mTORC activity in B cells, at different 
stages of development, indifferent B cell subsets, and in response to diverse types of 
stimulation.  My finding that glutamine uptake and metabolism are required for 
mTORC1 activity following anti-Ig stimulation of naïve B cells provides a novel 
mechanism of mTOR regulation that was previously unknown.  
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Nutrients contribute to LPS induced differentiation 
 Unlike anti-Ig, LPS stimulation induces the proliferation and differentiation of B 
cells into Ig-secreting plasma cells.85,133,232 Prior to proliferation, the cell membrane 
content doubles, and during differentiation the interior of the cell undergoes a substantial 
morphological change.145,233   Expansion of the rough ER and Golgi network is induced, 
to cope with the demands of production and secretion of large amounts of Ig.235  Distinct 
changes in the ER network manifest as early as 24 h after exposure of naive B 
lymphocytes to LPS.145,233  To meet the demands of increased membrane content, B cells 
undertake de novo lipid synthesis, which can be accomplished by shuttling carbon, from 
nutrients such as glucose or glutamine, into acetyl-CoA production and subsequent 
synthesis pathways for fatty acids.246-250  LPS stimulation of B lymphocytes promotes an 
increase in ACLY enzymatic activity, the rate-limiting enzyme in the production of 
acetyl-CoA, as well as phosphorylation of ACLY on serine 454, which leads to 
increased catalytic activity.133,251  Previous work by the Chiles lab showed that ACLY 
activity is required for glucose-dependent de novo lipogenesis.  This has been 
demonstrated by inhibition of glucose incorporation into fatty acid, cholesterol, and 
neutral and acidic lipids following treatment of B cells with the selective ACLY 
inhibitor 2-hydroxy-N-arylbenzenesulfonamide (Compound 9, C-9).133  Further, this 
work revealed that the majority of acetyl-CoA used to support de novo fatty acid 
synthesis following LPS stimulation is derived from glucose and not glutamine. Taken 
together, these results point to a key role for ACLY activity in regulating glucose-
dependent de novo lipogenesis in LPS-stimulated B lymphocytes.  Several of the lipids 
identified whose de novo synthesis is increased in response to LPS, such as 
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phosphatidylinositol (PI), play critical roles in B lymphocyte signaling and/or 
differentiation.19,52 Additionally, synthesis of phosphatidylcholine (PC), the most 
abundant membrane phospholipid and the primary phospholipid in the ER compartment, 
was found to increase following LPS stimulation.233,246  
Based on these results, I investigated whether ACLY activity was necessary for 
ER expansion and B cell differentiation.  My results showed that impaired de 
novo lipogenesis, resulting from ACLY inhibition, correlated with an inability to 
physically expand the ER compartment in B lymphocytes stimulated with LPS.  To 
examine the effects of ACLY inhibition on B cell differentiation, I was able to monitor 
the expression of several B cell differentiation markers by flow cytometry in viable 
lymphocyte populations treated with the small molecule ACLY inhibitor 3,3,14,14-
tetramethyl-hexadecanedioic acid (Medica 16) and/or C-9. LPS-induced surface 
expression of CD138, a marker for B cell differentiation, was reduced following 
inhibition of ACLY activity. The increased expression of Blimp-1 in LPS-stimulated 
splenic B cells was also reduced in the presence of Medica 16.  These findings support a 
role for ACLY activity in B cell differentiation to a plasma-like phenotype.  
 
A putative role for glutamine in the production of B10 regulatory cells 
In order to identify the physiologic relevance for glucose and glutamine in B 
cells, I evaluated the impact of glucose or glutamine depletion on antigen presentation 
by B cells.  Antigen presentation is a very early event in the response of B cells to 
antigen exposure and requires BCR-mediated endocytosis of antigen followed by 
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delivery to the lysosome, where it is then processed and complexed with MHCII and 
transported to the cell surface.76,102,238 With this in mind, I sought to initially determine if 
glucose or glutamine were required for BCR endocytosis and trafficking to the 
lysosome. Studies carried out in collaboration with the Folker laboratory revealed that in 
naïve, antigen-inexperienced B cells, antigen endocytosis and trafficking to the lysosome 
as measured by colocalization of BCR and the lysosomal marker LAMP-1 was not 
impacted by the availability of extracellular glucose or glutamine.237  This finding is 
consistent in the context of my results indicating that very early activation events prior to 
24 hours following anti-Ig stimulation are not nutrient dependent.  BCR endocytosis 
occurs rapidly following antigen encounter, and colocalization under normal conditions 
can be observed between 15 and 60 minutes.102,238  BCR endocytosis can be observed in 
cells that have been primed with LPS stimulation for several days, and future 
experiments will aim to establish whether antigen trafficking is impacted by nutrient 
availability in the primed B cells, as the activation in the absence of nutrients may 
impact lysosomal structure or endocytotic pathways at later times. 
I also evaluated whether glucose or glutamine might be required for the 
differentiation of B cell regulatory subsets.  Using an in vitro system developed by the 
Tedder laboratory to generate B10 cells from naïve splenic B cells, initially by LPS 
stimulation followed by PMA and ionomycin treatment, my experiments revealed that 
glutamine is required for LPS-induced differentiation of CD5+ CD1dhigh IL-10 secreting 
regulatory B cells in ex vivo cultures.207  IL-10 secretion was found to be abolished in the 
absence of glutamine, as measure both by flow cytometry and ELISA.  Treatment of B 
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cells during LPS stimulation with the ASCT2 inhibitor GPNA also blocked 
differentiation of B10 cells, demonstrating the importance of ASCT2 mediated 
glutamine uptake for differentiation.  Interestingly, these findings differ to studies 
examining the role of glutamine in T cell differentiation, wherein glutamine depletion or 
ASCT2 knockout in mice resulted in increased differentiation into regulatory 
subsets.162,190,191,239  My results utilize and in vitro system using wild-type cells, whereas 
this study in CD4+ T cells examined a knockout mouse in which all tissues/cell types 
lack ASCT2.   Therefore, my findings are cell intrinsic whereas the T cell effect could be 
T cell extrinsic, for instance the development of CD4+ T cells could be skewed towards 
a non-regulatory subtype prior to activation.  B10 cells are found in mouse spleen at low 
frequencies (1-3%), and can be induced in vitro by diverse sets of stimuli, including 
LPS, CD40, and PMA plus Ionomycin.110,207 It is now known that a subset of progenitor 
B10 cells (B10pro) exists that can give rise to IL-10 secreting B cells, however this 
subset and their role in the generation of the total B10 cell population remains poorly 
understood, as do molecular mechanisms of B10 differentiation.207,252,253 This 
differentiation appears to be at least somewhat BCR dependent, however IL-10 secretion 
can occur in response to diverse stimuli (i.e., CD40, LPS, anti-Ig).207,254,255  Signaling 
through cell surface receptors that recognize these signals drives B10 differentiation and 
confers the characteristic suppressive phenotype, but the exact signaling pathway is 
poorly understood.253,256-258  My results are the first to suggest a role for a nutrient 
molecule (i.e., glutamine) in the generation of a regulatory B cell (i.e.,B10), and reveal 
an important new finding that B cell differentiation is impacted by nutrient availability.  
Previous work has shown that B10 differentiation is correlated with plasma-like 
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differentiation marker CD138, and is dependent on Blimp-1.259 My work has also 
demonstrated the importance of the nutrient glucose to plasmablast differentiation, and 
interplay between these two nutrients could support B10 differentiation as well.  A 
differential requirement for these two nutrients during early activation in response to 
anti-Ig stimulation was also demonstrated; it is possible that they support different 
responses during later LPS-induced differentiation events.  For instance, I have 
demonstrated that glucose supports lipid biosynthesis and ER expansion which 
contributes to plasmablast differentiation, perhaps glutamine contributes to an alternative 
growth response such as resident ER protein synthesis, or calcium uptake. 
 
Translational significance to human health 
Although the work herein was carried out the immune system of the mouse as a 
model system, these results have potential applications to human health, especially when 
viewed in the context of other’s work.   For instance, it has been described that victims 
of burns have decreased circulating blood glutamine concentrations.260,261 This could be 
significant given that burns, being wounds, create an increased susceptibility to 
infection.  Low glutamine levels could impair the mounting of an effective B cell 
response, given my demonstration that activation is severely impaired in the absence of 
glutamine.  Recent work that has shown nutrient availability contributes to perturbations 
in T effector subset differentiation has led to a new interest in the role that nutrients 
might play in autoimmune disease.206  Emerging studies show that altered nutrient states 
exist in diseases including EAE and MS, in particular altered blood concentrations of 
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glutamine and glutamate.162,262-264  This opens the possibility that these altered nutrient 
states are contributing to disease state through activation or differentiation of T, or as 
shown in the work described herein, B cells.  This is especially exciting given my 
findings that L-glutamine availability regulates differentiation into the regulatory B10 
subset.  This cell subset has been demonstrated to play a significant role in regulating T 
cell autoinflammatory responses.111-113  Impaired B10 differentiation due to altered 
nutrient availability could potentially speed up or increase disease symptoms.	
When considering the potential relevance to human health, it is important to note 
the limitations of an in vitro system.  While the mouse provides a practical model system 
for the study of B cells, it is important to note differences in B cell biology between mice 
and humans.  For instance, in the mouse circulating levels of B cells are proportionally 
much higher that that in human.265,266  Further, human B cells are unable to respond to 
LPS stimulation due to a lack of TLR4 receptors.267 This makes the study of glutamine 
contribution to LPS derived B10 cells difficult to compare to human regulatory B cells. 
Additionally, cells manipulated in vitro may not always accurately represent conditions 
cells would encounter in vivo.  It is important to consider the role that other cells, such as 
T cells or other immunes cells that would normally be in the B cell environment, may 
have during B cell responses.  Manipulation of isolated cells does, however, provide the 
only practical means to strictly control concentrations of specific nutrients that would be 
difficult or impossible to regulate in a living organism. 
 
Summary and Future Directions 
 The results outlined in my thesis shed light on the differences in the regulation 
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and utilization of glucose and glutamine during the B cell activation response.  
Interestingly, although an absence of glutamine results in an early block at G1 entry, with 
only the earliest of activation events able to proceed, glucose depletion inhibits but does 
not abolish activation events up to and including S phase entry during anti-Ig 
stimulation.  Glucose is however an important contributor of carbon to de novo lipid 
synthesis for ER expansion and induction of plasma-like differentiation following 
proliferation under LPS stimulation.  Importantly, early glutamine uptake and 
metabolism aids in the induction of Glut1 expression and glucose uptake in an mTORC1 
dependent manner.  Together, this provides an interesting potential timeline in which 
early glutamine uptake and metabolism helps to regulate glucose uptake that although 
not essential during early activation and cell cycle entry, becomes critical at later stages 
of the B cell response.  My results also identify ASCT2 as a critical glutamine importer 
during these described B cell responses, and characterize a transport system for 
glutamine that has not previously been examined in B cells.  Further, glutamine is 
required for differentiation into B10 cells following LPS treatment.  This finding 
represents a heretofore-unknown regulatory role of glutamine during B cell activation, 
and could potentially have relevance in vivo in nutrient depleted microenvironments in 
the periphery of the immune system.  
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Figure 3.  Timing of nutrient requirements during B cell activation and differentiation.  
Glutamine depletion results in as early block in cell growth responses, while glucose is 
essential for de novo lipid synthesis and plasma-like differentiation.  Glutamine is also 
essential for IL-10 secretion at later stages of activation, although the exact timing of this 
block in differentiation is unknown. 
 
Future work in this project will aim to further study the importance of ASCT2 to 
B cell maintenance and activation.  The ASCT2 knockout mouse provides an excellent 
opportunity to examine the requirements for glutamine in a living system, where 
concentrations of glutamine may vary.162  Use of this model will enable us to also 
examine development of B10 cells in vivo, uncovering additional earlier time points 
during which ASCT2 is required.  For instance, many B10 cells arise from the B-1 
subset of B cells, and deletion of ASCT2 might inhibit the development of these cells 
early on, leading to a phenotype of decreased Breg populations in adult mice.  
Additionally, we will seek to determine the contribution of glutamine metabolism to LPS 
induced differentiation.  Glutamine can support a variety of metabolic processes, 
including generation of ATP through the TCA cycle.  This work has demonstrated the 
importance of initial steps of glutamine metabolism to support α-KG production and 
mTORC1 activation, however it is highly likely that glutamine is metabolized further to 
provide substrates for biosynthetic reactions, as well as to support energy production.  
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Although my studies have determined the importance of α-KG production from 
glutamine to support B cell responses, future experiments should aim to address the 
other pathways of glutamine metabolism and their role during B cell activation and 
differentiation.  This question can be addressed using commercially available inhibitors 
of specific enzyme catalyzed steps in the metabolism of glutamine to determine their 
importance to B cell responses.  Finally, there is much further investigation to be done 
into the requirement for glutamine during B10 differentiation.  My work has established 
that ASCT2 mediated glutamine uptake is required to induce B10 differentiation in vitro 
following LPS stimulation, however the precise role remains to be determined.  Very 
little is known about the molecular mechanisms regulating B10 differentiation, however 
a good starting point would be to determine the role of glutamine in response to different 
stimuli (i.e., CD40, LPS), as these stimuli have been shown to differentially induce B10 
production.  Additionally, glutamine metabolism could be inhibited to determine the 
importance of production of various glutamine derived metabolites.  This could identify 
one or more specific metabolic programs that glutamine contributes to that are essential 
for B10 differentiation. 
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